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ABSTRACT 
Breast cancer continues to be the leading cause of cancer-related 
death in women worldwide. I n  this d issertation ,  natural compounds with 
anti -breast cancer activities were identified . We investigated the effect of 
Sa l inomycin ,  a potassium ionophore isolated from Streptomyces albus, on 
the survival of th ree human breast cancer cell l ines MCF-7,  T47D and 
M DA-MB-23 1 .  High concentrations of Sal inomycin induced a G2 arrest, 
down regulation of surviv in and triggered apoptosis. I nterestingly, 
treatments with low concentrations of Salinomycin induced a transient G1  
arrest at an earlier t ime and G2 arrest and senescence, associated with 
enlarged cel l morphology, at a later t ime. There was a lso an upregulation 
of p2 1 protein ,  an increase in H istone H3 and H4 hyperacetylation and 
expression of SA-f3-Gal activity. Furthermore, i t  was found that 
Sa l inomycin was able to potentiate the ki l l ing of the MCF-7 and MDA-MB-
2 3 1  cel ls ,  by the chemotherapeutic agents, 4-Hydroxytamoxifen and 
frondoside A, We also investigated the effect of Origanum majorana, a 
cu l inary herb, ethanol ic extract (OME)  on the surviva l ,  migration ,  invasion 
and tumor growth of the h igh ly prol iferative and invasive triple-negative 
p53 mutant breast cancer cell line MDA-MB-231 . We found that OME 
inh ibited the viabil ity of M DA-MB-23 1  breast cancer cel ls  both in vitro and 
in vivo. OME was found to el icit anti-breast cancer activity by inducing 
m itotic arrest, DNA damage and triggering the extrinsic apoptotic pathway. 
Moreover, OME was found to i nduce down regulation of survivin , 
an i mportant therapeutic target against breast cancer. 
iv  
OME was also found to inh ibit cell m igration and invasion,  two major 
events required for tumor metastasis. Our data are the first to l ink 
senescence and h istone modifications to Salinomycin which provides a 
new insight to better understand the mechanism of action of Sal inomycin ,  
at least i n  breast cancer cel ls .  Moreover, o u r  fi ndings provide strong 
evidence that O. majorana may be a promising chemopreventive and 
therapeutic candidate against cancer especial ly for highly invasive triple 
negative p53 mutant breast cancer; thus val idating its use in  alternative 
medicine. 
Keywords: Breast Cancer, Apoptosis ,  DNA Damage, H istone 
Hyperacetylation , p2 1 ,  Sal inomycin ,  Origanum majorana, Senescence­
Associated Beta Galactosidase (SA-I3-Gal), Mitotic Arrest. 
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CHAPTER 1 :  INTRODUCTION 
1 . 1 Breast Cancer 
Breast cancer is  the leading cause of cancer-related death in 
women worldwide. Approximately one-th ird of al l  women with breast 
cancer develop metastasis and ult imately die as a result of the effects of 
the disease The American cancer society estimated nearly 232 ,670 new 
cases and about 40,000 deaths estimated due to breast cancer in women 
in 20 1 4  [ 1 ] .  According to the UAE Min istry of Hea lth , breast cancer is the 
most common mal ignancy d iagnosed among women in the UAE. Women 
in the UAE tend to develop breast cancer at least a decade earl ier than 
their counterparts in  the West, according to a study [2 1 0] .  Remarkable 
progress has been made in  the treatment of breast cancer over the years 
with hormonal therapy for estrogen receptors and/or progesterone 
receptors positive tumors, as wel l  as other therapies. However, despite 
these advances, breast cancer remains a frequent cause of death in  
women. 
1 .2 Tri pe Negative Breast Cancer 
Triple-Negative Breast Cancer (TNBC) i s  a subtype of breast 
cancer characterized by tumors that do not express estrogen receptors 
(ER),  progesterone receptors (PR), or human epidermal growth factor 
membrane receptors (H ER-2).  It comprises about 1 5% of a l i  breast cancer 
cases [2] .  It is characterized by its un ique molecular profi le,  aggressive 
behavior, and d istinct pattern of metastasis, includ i ng lung,  l iver and bra in 
metastasis [3] . Epidemiological studies showed a h igh prevalence of trip le 
negative breast cancer among younger women and those of African 
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C HAPTER 1 :  INTRODUC TION 
1 . 1 Breast Cancer 
Breast cancer IS the leading cause of cancer-related death in  
women worldwide. Approximately one-th i rd of  a l l  women with breast 
cancer develop metastasis and ult imately d ie as a result of the effects of 
the d isease The American cancer sOciety estimated nearly 232,670 new 
cases and about 40 ,000 deaths estimated due to breast cancer in  women 
in 20 1 4  [ 1 ] .  Accord ing to the UAE Min istry of Hea lth , breast cancer is the 
most com mon mal ignancy d iagnosed among women in the UAE. Women 
In the UAE tend to develop breast cancer at least a decade earl ier than 
their counterparts in  the West, according to a study [2 1 0] . Remarkable 
progress has been made i n  the treatment of breast cancer over the years 
with hormonal therapy for estrogen receptors and/or progesterone 
receptors positive tumors, as wel l as other therapies. However, despite 
these advances, breast cancer remains a frequent cause of death in  
women.  
1 .2 Tripe Negative Breast Cancer 
Triple-Negative Breast Cancer (TNBC) is a subtype of breast 
cancer characterized by tumors that do not express estrogen receptors 
(ER) ,  progesterone receptors (PR), or human epidermal growth factor 
membrane receptors (H E R-2) .  It comprises about 1 5% of a l l  breast cancer 
cases [2] .  It is  characterized by its unique molecular profi le,  aggressive 
behavior, and d ist inct pattern of metastasis, includ ing lung,  l iver and brain 
m etastasis [3] . Epidemiologica l  studies showed a high prevalence of triple 
negative breast cancer among younger women and those of African 
1 
descent. TNBC has a poor prognosis and relapse quickly compared with 
other subtypes of breast cancer that are positive for hormonal receptors or 
H E R2 membrane receptors [4] . 
Gene-expression profi l ing approaches demonstrated that TNBC is 
a heterogeneous group of diseases com posed of d ifferent, molecularly 
d ist inct subtypes [4 , 5] .  Although not synonymous, the majority of TNBC 
share morphologica l  and genetic abnormal it ies with basal- l ike breast 
cancer, a subgroup of breast cancer defined by gene-expression profi l ing ,  
where TNBC con stitutes approximately 80% of a l l  basal- l ike tumors. 
However, several stud ies have shown that TNBC includes tumors with a 
non-basal expression profi le and , in particu lar, normal-breast, the mult iple 
markers negative, as  wel l  as the recently identified claudin-negative 
subtype [4 , 5] . TNBC a lso has molecular features that overlap with breast 
cancer, B RCA- 1 germ l ine mutation , and is a lso associated with p53 
m utations [2 , 6] . 
TNBC represents an important cl in ical  cha l lenge because these 
types of cancer do not respond to hormonal therapy or other avai lable 
treatments . Despite advances in  the treatment of hormone receptors ( H R) 
and human epidermal growth factor receptors ( HER2)-positive breast 
cancers, the prospects for women with TNBC remains poor and 
conventional chemotherapy remains the main treatment of TNBC even 
though TNBC becomes h igh ly resistant [7] . Precl in ica l  and cl in ical  studies 
have suggested several agents that are active in  TNBC. These agents 
include DNA-damaging agents and poly (ADP-ribose) polymerase (PARP) 
inh ibitors wh ich are active in  TNBC associated with B RCA1 dysfunction . 
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Anti-epiderm al growth factor receptors (EGFR) antibodies and EGFR 
tyrosine k ina se inh ibitors are active in  TNBC with EGFR gene 
ampl ificatio n .  Dasati nib is active in  TNBC with activated Src tyrosine 
kinase and inh ibitors of mammal ian target of rapamycin (mTOR) are 
active in  TNBC with loss of PTEN tumor suppressors. Anti-angiogenic 
therapies were shown to enhance antitumor activity of chemotherapeutic 
agents in h ypervascular TNBC. To develop novel strategies against 
TNBC,  it i s  essentia l  to understand the pathways driving the aggressive 
behavior of these types of cancer [8- 1 0] .  
1 .3. Cancer Metastas is 
Cancer m etastasis starts in  the primary tumor site when cancer 
cel l s  start to invade and degrade the basement membrane and 
extracel lu lar  matrix (ECM) to get into the vascu lar or lymphatic circu lation 
system .  Loss of cel l to cell adhesion , induces the d isassembly of cancer 
cel ls  from the primary tumor, d issemi nating to d istant sites through blood 
vessels and lymphatics, and eventua l ly  they leave the circulation to 
estab l ish m etastasis in  d istant organs [ 1 1 ,  1 2] .  E-cadherin ,  a cel l-cel l  
adhesion molecule, plays a major role in  the  establ ishment and 
maintenance of normal t issue arch itecture. I t  i s  expressed predominantly 
on the surface of normal epithel ia l  cel l s. For cancer cel ls to become 
m etastatic, they must decrease E-cadherin expression and break cel l-cel l 
adhesions and induce cel l mobi l ity triggering a transition from tumorigenic 
(epithe l ia l )  to migratory/ invasive (mesenchymal)  phenotype ending in 
tumor metastasis. Hence, the expression level of the epithel ial cadherin 
(E-cadherin )  has become an important ind icator of these transitions [ 1 3, 
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1 4] .  Therefore, searching for agents that cou ld enhance E-cadherin 
expression is therapeutic aim in order to repress the metastatic potential 
of cancer cel ls .  
The adherence of tumor cel l s  to endothel ial cel ls is an essential 
step d u ring cancer progression and metastasis. Several adhesive 
molecules, such as intracel lu lar adhesion molecule-1 (I CAM-1 ) ,  have 
been identified as being responsible for the endothel ial adhesion of cancer 
cel l s  [ 1 5] .  Whi le ICAM-1 expression was found at low basal levels in many 
cell types,  i ncluding epithel ial and endothel ia l  cel ls [ 1 6], its expression as 
a solub le  serum ICAM-1 were found to be h igh in metastatic breast cancer 
patients [ 1 6] .  Therefore, agents that repress ICAM-1 expression in breast 
cancer cel ls ,  and subsequently block the interaction between cancer and 
endothel ia l  cel is ,  m ight be an impo rtant therapeutic target for repressing 
the m etastatic potential of cancer cel ls .  
1 .3 . 1 . Tumor Cel l  I nvasion i n  Cancer Metastasis 
Degradation of the extracel lu lar  matrix (ECM) surrounding the 
primary tumor is  an essential step in tumorigenesis. This degradation is 
important  for t issue remodeling and the induction of angiogenesis, and is 
main ly mediated by specific proteolyt ic enzyme systems main ly matrix 
m etal ioproteinase (MMPs) and u rokinase plasminogen activator (uPA). 
Among MMPs,  upregulation of M MP-2 and MMP-9 was shown to be 
associated with breast cancer metastasis and poor cl in ical  outcomes [ 1 7]. 
Northern blot analysis revealed that the level of MMP-2 and MMP-9 
m RNA was h igher in breast cancer t issues compared to normal breast 
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t issue [ 1 8] .  I n  addition , h igher MMP-9 protein  concentration was detected 
in breast cancer t issue when compared to normal breast ti ssue [ 1 9] .  
S imi larly,  h igher protease activity for M M P-2 and MMP-9 was detected by 
zymography i n  tumor t issues compared to norma l  t issues [20]. 
MMPs are d i rectly activated by Serine Protease Plasmin ,  which is 
activated from i ts proenzyme form (plasminogen) by serine protease 
urokinase-type plasminogen activator (uPA) u pon binding to cel l  surface 
receptors (uPAR). Overexpression of uPA has been found in many tumor 
types and is  correlated to a poor prognosis .  Moreover, binding of u PA to 
u PAR a lso induces signal transduction ,  a l lowing enhanced cell m igration 
[ 1 7 ,  2 1 ,  22] .  Therefore, regulating the expression of ECM degradation 
enzymes is another therapeutic target to control breast cancer. 
1 .3 .2 .  Angiogenesis in Cancer Metastasis 
Ang iogenesis is a complex mu ltistep process involving solub le 
factors, adhesion molecules, proteases and cytokines. The process of 
tumor angiogenesis starts when tumor cel ls secrete and activate 
angiogenic  factors, thereby activating proteolytic enzymes. At th is t ime, 
endothel ia l  cel l s  prol iferate, m igrate, and d ifferentiate. 
Vascular  endothel ia l  growth factor (VEGF)  is the most prominent 
mediator in tumor angiogenesis that is induced in  breast cancer [23] . Up­
regulation of VEGF expression has been reported in  a variety of mal ignant 
human cancers i nclud ing breast, colon , and lung cancers. An in  situ 
hybridization study of human breast samples showed high VEGF 
expression i n  tumor cel ls but  not in  the normal duct epithel ium [24] . 
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Hence, VEGF might be a good target in  the treatment of breast cancer 
patients. 
1 . 3 .3 .  Nuc lear Factor KB ( N FKB) in Cancer Progression and 
Metastasis 
Nuclear Factor KB (N FKB) ,  (a transcription factor), is  a key player in 
cancer m etastas is  [ 1 1 ] . I t  has been shown that several genes involved in  
tumor m etastasis are d i rectly regu lated by NFKB.  The frequent over­
expression of N FK B  in tumor cel ls suggests that selected tumor cel ls  may 
acqu i re metastatic activity via aberrant expression of metastasis relevant 
genes during their progression. In fact, studies showed that MMP-2 and 
MMP-9 [25 ,  26] ,  u PA [27 ,  28], u PAR [29] and ICAM-1 [30] are 
downstream targets of the NFKB signa l ing pathway. NF-KB provides 
mechanist ic l inks between inflammation and cancer, and moreover, 
regu lates tumor angiogenesis and invasiveness, ind icating that signal ing 
pathways that m ed iate their  activation provide attractive targets for new 
chemothera peutic approaches [ 1 1 ] . 
1 .4. Program med Cel l  Death throug h  Apoptosis 
Apoptosis ,  a major form of programmed cel l  death , is  a defense 
mechan ism and a tumor suppressor pathway essential for the 
development and maintenance of cel lu lar  homeostasis. When deregulated 
apoptosis  leads to an uncontrol led prol iferation of damaged cel ls .  It a lso 
leads to resistance to chemo and radio therapy [3 1 ] . Apoptosis can be 
triggered by d iverse cel lu lar signals .  These include intracel lu lar signals 
produced in  response to cel lu lar stress, such as increased intracel lu lar  
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Ca2+ concentration,  DNA damage and high levels of reactive oxygen 
species (ROS). Extrinsic inducers of apoptosis include bacterial 
pathogens, tox ins ,  ni tric oxide,  growth factors and hormones [32]. 
Apoptosis is regu lated by a series of signal ing cascades and occurs via 
two con nected pathways. The extrins ic pathway is in i tiated by cel l surface 
death receptor stimu lation and activation of caspase-8, whi le the intrinsic 
pathway involves cytochrome c release from mitochondria and 
subsequent caspase-9 activation .  Activated caspase-8 and-9 activate 
executioner caspases, including caspase-3, which in turn activate a 
cytoplasmic endonucleases and proteases that degrades nuclear 
materia ls  and nuclear and cytoskeletal proteins ,  respectively, resu lti ng in 
el im ination of abnormal cel ls [33] . Evasion from apoptosis is a ha l lmark of 
cancer cel l s  leading to an uncontro l led prol iferation of damaged cel ls  and 
contribut ing to cancer development that enhances resistance to 
convent ional  a nti -cancer therapies, such as radiation and cytotoxic 
therapies.  Most chemotherapeutic agents induce cancer cel l  death by the 
activation of the apoptotic pathway. However, most current 
chemotherapeutic drugs are associated with cytotoxic side-effects and the 
development of chemo-resistance [34, 35] .  
1 . 5. Ce l l  Cycle Control 
The cel l cycle i s  series of integrated events control led by a complex 
series of cel lu lar  and molecular s ignal ing pathways by which a cel l grows, 
repl i cates its DNA and divides. This process a lso includes mechanisms to 
ensu re the fidel ity of genetic material and corrects errors through 
checkpoints; if not, the cel ls  commit su icide (apoptosis) [36, 37]. 
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The cel l  cycle consists of four  phases (G 1 ,  S ,  G2 and M) I t  
governs the transition from qu iescence (GO) to cel l  prol iferation . As a cel l  
a pproaches the end of the G1 phase ,  it is  control led at a checkpoint, 
cal led G 1 /S ,  where the cell determi nes whether or not to repl icate its DNA. 
At this checkpoint the cell is checked for DNA damage to ensure that it 
has  al l the necessary cel lu lar  machinery to a l low for successful cel l  
d ivision .  As a result of th i s  checkpoint ,  which involves the interaction of 
various proteins, a molecu lar switch i s  switched on or off. Cel ls with intact 
DNA continue to S phase wh i le  cel ls  with damaged DNA are arrested and 
com m it suicide through apoptosis ,  or programmed cell death . A second 
such checkpoint occurs at the G2 phase fol lowing the synthesis of DNA in  
S phase but  before cel l d ivision in  M phase [38 , 39] . 
I n  eukaryotes, regu lation of the cell cycle is control led ,  in  part, by a 
fami ly  of protein  kinase complexes, and each complex is composed 
m in imal ly of a cata lytic subunit ,  the Cycl in Dependent Kinases (CDKs), a 
specific enzyme fami ly that uses signals to switch on cell cycle 
m echan isms. At least n ine structural ly related CDKs (CDK1 - CDK9) have 
been identified .  CDKs themselves are activated by forming complexes 
with an essential activating partner, cycl in ,  and another group of 
regu latory proteins that are on ly present for short periods in the cel l  cycle. 
These complexes are activated at specific intervals during the cel l cycle 
by phosphorylation at specific sites on the CDK by CDK-activating kinase 
(CAK),  but can a lso be induced and regu lated by exogenous factors. 
During the progression of the cel l  cycle, the cycl in-CDK complexes are 
subject to inh ibition through b inding with a class of proteins known as 
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Cycl i n  Dependent Kinase Inh ibitors (CDKls) ,  such as the C I P/KIP and 
I N K4 fam i l ies of proteins [37 , 40-42]. 
In mammal ian cel ls  CDKls  are grouped into two classes: (1 ) p2 1 
(Cip1 IWaf1 /Cap20/Sd i 1 /Pic1 ) ,  p27 (Kip1 ) ,  and p57 (Kip2) are related 
protei ns with a preference for Cdk2-and Cdk4-cycl in  complexes, (2) also 
p 1 6 1nk4a,  p1 51 nk4b, p 1 8lnk4c, and p1 91  nk4d are closely rel ated CDKls 
specific for Cdk4- and Cdk6-cycl in  complexes [43]. For instance, following 
stress signal s  or DNA damage, p2 1 and p27 bind to cycl in -CDK 
complexes to inh ibit thei r  cata lytic activity, stop the cel l  from proceeding to 
the next phase of the cel l  cycle and induce cel l-cycle arrest at different 
phases [44] . 
A considerable number of cycl ins have been identified (cycl in A­
cycl in T).  The pattern of cycl in expression varies with a cel l 's progression 
through the cel l  cycle, and th is  specific cycl in  expression pattern defines 
the relative position of the cel l  with in  the cell cycle [45] . Cyclin D interacts 
with CDK2 ,  -4, and -6 and drives cell progression through G 1 .  The 
association of cycl in  E with CDK2 is active at the G 1 /S transition and 
d i rects entry i nto S phase. S phase progression is d i rected by the cycl in 
A1CDK2 complex, and the com plex of cycl in  A with CDK1 i s  important in 
G2. CDK1 /cycl in B is necessary for m itosis to occur [40, 46] . 
When functioning properly, cel l cycle regu latory proteins act as the 
body's own tumor suppressors by control l ing cel l  growth and inducing the 
death of damaged cells [40] .  However, any genetic mutations that cause 
the m alfunction or absence of one or more of the regu latory proteins at 
cel l  cycle checkpoints can result in a molecular switch being turned 
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permanently on, perm itting uncontrol led mul tip l ication of the cel l ,  leading 
to carcinogenesis, or tumor development [38] .  
1 .6. Cel l Cycle Control  and Cancer 
A dysregulation of the cel l cycle is a ha l lmark of cancer in which,  
contrary to normal cel l s, tumor cel ls undergo unrestricted growth without 
stopping at predeterm ined points in the cel l  cycle .  This is due to the 
inactivation of cri tica l COKls, or to overexpression of cycl ins. For instance, 
overexpression of cycl i n  0 1  has been associated with the development 
and progression of breast cancer [37, 47]. Thus, abrogation of cel l  cycle 
checkpoints through targeting COKs, COKls and/or cycl ins wou ld 
recapitu late cel l  cycle checkpoints that l im it a tumor cell's abi l ity to cycle, 
and th is  may induce an apoptotic cascade lead ing to cel l death [48]. 
Recent stud ies have suggested that cel l  cycle arrest in mal ignant cel ls is 
often associated with apoptotic cell death . In recent years, many studies 
have shown the involvement of cel l cycle regu lation-mediated apoptosis 
as a mechanism of cel l  growth inh ibition [59-51 ]  and such targeted 
therapy against cancer has become important as an ideal compound for 
the management of cancer. I n  cl in ical tria ls a series of targeted agents 
d irectly abrogate the cell cycle checkpoints at crit ica l  times and induce 
growth arrest to u lt imately make the tumor cell susceptible to apoptosis 
[52, 53] . Examples of such agents include synthetic cel l  cycle inh ibitors 
such as flavopiridol, olomoucine, roscovitine and puvalanol B wh ich are 
con sidered to be a new generation of anticancer drugs [41 ,  54]. 
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In teresting ly .  a number of natural  compounds exerted their anti­
cancer activities th rough the induction of cel l  cycle arrest at different 
phases. which i s  considered as a promising chemopreventive and 
chemotherapeutic strategy. using more efficient and less tOXIC agents. 
Examples of som e  natura l ly  occurring compounds that have Induced cell 
cycle arrest. include capsaicin (ch i l i  peppers ) kaemopferol (broccol i  and 
tea). apigen in  ( parsley and celery). tangeretin (citrus peels), catechins 
(tea). cyanid ing ( cherries and strawberries), 6-gingerol (ginger) and 
resveratrol (grapes and red wine)  [55- 57] .  
1 .7. Ce l l  Senescence 
Cell senescence is  a stable cel l  cycle arrest that occurs in normal 
cel ls  after a l im i ted num ber of cel l  divisions .  However, it is  now broadly 
defined as a physiologica l  program of term ina l  g rowth arrest [58] . I t  can be 
triggered by genetic man ipu lations or by different forms of stress such as 
treatment with chemotherapeutic drugs, rad iation or d ifferentiating agents 
[59]. Cel ls that undergo senescence do not prol iferate even under mitogen 
stimulation , they remain viable and metabol ica l ly active but are 
permanently growth-arrested and produce secreted proteins such as ECM 
com ponents that affect the growth of their  neighboring cel ls (with both 
tumor-suppressing and tumor-promoting activit ies) as well as tissue 
organ ization.  Even if not all of the tumor cel l s  are rendered senescent as a 
result of an inducing agent (Le. treatment), such cel ls  may provide a 
reservoir of tumor-suppressing factors that wi l l  inh ibi t  the growth of non­
senescent cel ls  [60] .  Growth arrest i s  achieved and maintained in  either 
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the G1 or G2/M stage of the cel l  cycle, i n  part ,  by increased expression of 
specific cycl ln-dependent kinase inh ibitors (CDKls) ,  including p 1 6n '4a , 
p21 waf1 and p27K'P1 [6 1 ] . 
Senescent cel l s  develop distinct and recognizable flattened and 
enlarged cel l  morphology with a prominent nucleus and increased 
cytoplasmic granu larity. Most notably, these cel ls  can be visual ized with a 
sta in ing technique that i s  a widely accepted and used as a marker, 
senescence-associated �-galactosidase (SA-�-gal )  activity, which is 
detectable by X-gal sta in ing at pH 6 .0 ,  reflecting an increased lysosomal 
mass of senescent cel ls ,  and sta ins the perinuclear compartment blue 
[62] . 
1 .8. Senescence i n  Cancer Therapy 
Cancer therapy has traditional ly been based on drug cytotoxicity 
that a ims to com plete the destruction of tumor cel ls to improve patient 
survival .  Th is involves treatment with a h igh dose of toxic compounds orl 
rad iation. These approaches may produce complete cel l  death with in a 
tumor, however, they have been found to cause severe side effects in 
patients and often develop drug resistance and relapse or progress to 
advanced pri mary and metastatic tumors [60] . An a l ternative strategy is  
the induction of  senescence, which permanently stop the proliferative 
capacity of cel l s  without i nducing cancer cel l  death (cytostatic tnerapy) . I t  
IS of cl in ica l  interest that cancerous cel l s  can be induced to a senescent 
state In vitro and in vivo with specific conventional anticancer treatments. 
The induction of senescence in cancerous cel ls  can sensitize cancerous 
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cel l s  more to chemotherapy or radiation but by uSing lower doses. A 
senescence-Induced response to chemotherapy has seen found to be 
induced by a wide variety of anticancer agents under conditions of 
m in imal  cytotoxicity. Recently ,  c l in ical studies uti l izing cytostatic 
treatments have shown promising prel iminary results where therapy 
induced senescence has been identified in tumors after radiation or 
chemotherapy [63-65]. Although senescence occurs only in a subset of 
treated cel l s, suggesting that these treatments may be as effective as 
cytotoxi c  therapies in  inducing permanent growth inh ibitory response in 
both ear ly and late stage cancers , l im iting tumor progression and 
provid ing equivalent or prolonged survival with reduced toxicity related 
side effects. Moreover, evidence suggests that therapy inducing 
senescence may function as a back-up response to therapy in cancer 
cel ls  in which apoptotic pathways are d isabled [66] . Therefore, activating 
senescence in tumor cel ls is  another attractive approach to cancer 
treatment. 
Senescence is  not the only anti-proliferative response that 
determ ines treatment responses In the absence of apoptosis .  Another 
principal m echanism for anticancer agents is mitotic catastrophe; cell 
death result ing from abnormal mitosis ;  which usual ly ends in the formation 
of large cel l s  with multiple micronu clei and uncondensed chromatin [67] .  
Etoposide- induced mitotic catastrophe in  HeLa cel ls  was greatly i ncreased 
when apoptosis was inhib ited by BCL-2 (68). Also ,  both mitotic 
catastrophe and senescence were shown to be induced in irradiated 
tumor cel l s  when apoptotic responses were suppressed (69). 
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1 .9. N atural  Sources As Potent ia l  Anti-Cancer Agents 
Among the potential a lternatives for treating cancer are anti-cancer 
agents from natural  sources such as plants and dietary phytochemicals ,  
marine organisms and microorganisms. Throughout h istory, nature has 
been a n  attractive and rich sou rce of new therapeutic compounds that 
have found many appl ications in cancer therapy, as a tremendous 
chemica l  d iversity can be found in m i l l ions of species of plants, animals,  
marine  organ isms and microorganisms [70] .  Over 70% of a l l  anti -cancer 
com pounds are either natural  products, or natural product-derived 
substances or their derivatives ( chemical ly-altered products) that were 
developed on the basIs of knowledge gained from smal l  molecules or 
macromolecules that exist in nature [7 1 ] .  Chemoprevention and 
chemotherapy by naturally occurring agents is now considered to be more 
effective, and they do not have large side-effect consequences compared 
to synthetic drugs. It is an inexpensive ,  readi ly appl icable, acceptable and 
accessible approach to cancer prevention and treatment [72] . 
Recent studies have shown that compounds isolated from natural 
sources have cytotoxic effects on  several types of cancer cel ls ,  l ike 
breast, colon , melanoma,  uterine ,  lung and leukemia cel ls .  Moreover, 
stud ies suggest that the consumption of food rich in fruit , vegetables and 
spices results in a lower inciden ce of cancers (stomach , oesophagus, 
lung ,  ora l  cavity and pharynx, endometrium,  pancreas and colon ) [56, 70, 
71 ] .  
Between 2001 and 2005,  fou r  new drugs derived from natural 
products were approved as ant i-cancer agents. The approved anti-cancer 
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agents doxorubici n ,  estradiol In  2002, cholorophyl l and I-aspartic acid in 
2004 and taxol nanopartlcles i n  2005 [73] . The marine a lkaloid 
trabectedin ,  epothi lone denvative ixabepl lone and temsirol lmus are three 
new drugs i ntroduced in 2007 that originated from microbial sources for 
the treatment of cancer [74] . 
1 .9 . 1 . P h ytochemica l s :  D ietary Source of Anti-Cancer Agents 
Phytochemica ls  are natural plant-derived compounds that have 
been shown to influence human health in many ways. Plants have been a 
rich source of h igh ly effective phytochemicals which offer great potential in  
the fight against cancer. More than 1 ,000 different phytochemica ls  have 
a l ready been prove to possess interesting chemo-preventing activities. 
Phytochemica l  a re becoming more attractive for cancer prevention and 
treatment because they were proven to be very effective, and do not have 
serious side-effects com pared to synthetic drugs and most importantly ,  
they can act on specific and/or mu lt iple molecu lar and cel lu lar targets. 
Recently, these natura l  compounds have become of increasing i nterest 
thanks to their health promoting properties, especial ly with regard to 
breast cancer treatment and prevention [7 1 ,  75] . 
I dentification and development of new chemotherapeutic agents 
from plants have been recognized in cancer therapy, and have become 
major areas for experimental cancer research . Various phytochemicals 
present i n  the diet were found to ( i )  k i l l  breast cancer cel ls in vitro and ( i i )  
prevent and/or suppress breast cancer progression in  various precl in ical 
an imal  models [76] . Phytochemica ls  have been shown to target breast 
cancer development and progression through inh ibiting cel lu lar 
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prol iferation ,  suppressing inflammatory processes, arresting cell cycles, 
inducing apoptosis, modulating gene expression such as upregulation of 
cytoprotective genes that encode for carcinogen detoxifying enzymes and 
antioxidant enzymes and/or upregulation of tumor suppressing genes that 
encode for tumor suppressor proteins that play an important roles in 
cel lu lar  signal ing pathways, and inh ibit ing ang iogenesis and Invasion 
potential of many metastatic cancer cell l i ne [77]. 
Thus ,  cel l  s ignal ing cascades and their interacting factors have 
become i mportant targets of chemoprevention and chemotherapy in which 
phytochemicals and plant based agents seem to be effective. The 
m echan ist ic i nsight into chemoprevention further includes induction of cell 
cycle arrest and apoptosis, or inh ibit ion of signal transduction pathways, 
ma in ly the mitogen-activated protein  kinases (MAPK), protein kinases C 
( PKC) ,  phosphoinositide 3-kinase ( P I3K) ,  glycogen synthase kinase 
( GS K) which lead to abnormal cyclooxygenase-2 (COX-2) ,  activator 
prote in - 1  (AP- 1 ) ,  N F-KB and c-Myc expression .  The effectiveness of 
chemopreventive agents reflects their abi l ity to counteract certa in  
upstream s igna ls  that lead to genotoxic  damage, redox imbalances and 
other forms of cel lu lar stress [77]. 
B ioactive natural compounds and the modulated molecu lar targets 
identified through extensive research can be the basis for how these anti­
can cer agents can potential ly be used for the prevention and treatment of 
can cer. However, a lack of success with targeted monotherapy, resulting 
from evading mechanisms, has forced researchers to employ either 
combination therapy or agents that i nterfere with mu ltiple cel l -signaling 
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pathways. N umerous anti -cancer agents and phytochemica ls  identified 
from plants can interfere with cel l-signal ing pathways . Examples of 
anticancer drugs derived from plants and currently in cl in ica l  use include 
the vinca alkaloids (vinblastine and vincristine) isolated from Catharanthus 
roseus. The Vinca alkaloid was responsible for an increase in the cure 
rates of some forms of leukemia [78]. Vincristine was shown to inh ibit 
m icrotubule assembly, i nducing tubul in self-association into coi led spiral 
aggregates [78] . Etoposide is  an epipodophyl lotoxin ,  derived from the 
m a ndrake plant Podophyllum pe/tatum and the wild chervi l Podophyllum 
emodi [79] and displayed significant promise against smal l-cell lung 
carcinomas [80] . Etoposide is a topoisomerase I I  inh ibitor, stabi l izing 
enzyme-DNA cleavable com plexes leading to DNA breaks [8 1 ] . The 
taxanes pacl itaxel and docetaxel show antitumor activity against breast, 
ovarian and other types of tumor in cli n ical tria ls.  Pacl itaxel  stabi l izes 
m i crotubu les leading to mitot ic arrest [82] .  In addition, the camptothecin 
derivatives i rinotecan and topotecan ,  have shown significant antitumor 
activity against colorectal and ovarian cancer, respectively [83, 84] . These 
later com pounds were in itia l ly obtained from the bark and wood of 
Nyssacea Camptotheca accuminata and act by inh ibit ing topoisomerase 
[85]. The taxanes and the camptothecins are approved for human use in 
various countries. 
Synthetic flavone,  a cyclin-dependent kinase inh ibitor, derived from 
roh itukine, is  a plant a lkaloid isolated from the leaves and stems of 
Oysoxy/um binectariferum [86 ,  87] .  F lavopiridol represents the first cycl in­
dependent kinase inh ibitor to enter cl in ical tria ls [88] . Its mechanism 
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i nvolves interfering with the phosphorylation of cycl in -dependent kinases 
and arresting cel l -cycle progression at the growth phases G1 or G2 [89, 
90] .  
Homoharringtonine,  another alkaloid isolated from the 
Cepha/otaxus harringtonia tree, is efficient against various forms leukemia 
[9 1 ,  92]. I ts mechanism involves the inh ibition of protein  synthesis and 
blocking cel l-cycle progression [93] . DNA topoisomerase I inhibitor �­
lapachone, orig ina l ly  obtained from the Lapacho tree, induces cell-cycle 
delay at the G1 or S phase before induci ng either apoptotic or necrotic cell 
death in a variety of human carcinoma cel ls ,  i ncluding ovaries, colon, 
l u ngs,  prostate and breast [94] . Moreover, there are many plants which 
are known to suppress cancers that need further stud ies to val idate their 
potential anticancer activit ies. Examples include Salvia officina/is, Viscum 
a/bum, Broussonetia papyrifera, Euphorbia heterophylla, and Viscum 
calcaratum. About 1 1 7 p lants were reviewed i n  ref. [70] for their anti­
cancer activity. 
1 .9 . 1 . 1 . Origanum majorana 
Origanum majorana belongs to the fam i ly Lam iaceae. I t  is 
commonly known as marjoram.  I t  is a perennia l  herb and widespread 
worldwide. A large number of known species of the genus Origanum are 
ut i l ized worldwide as spices and flavoring agents and have a long h istory 
of both cul inary and medicinal  use. O. majorana is used as a home 
remedy for chest infections ,  coughs, sore throats, rheumatic pains, 
nervous d isorders, stomach d isorders, cardiovascular d isease and skin 
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care [95 ,  96]. Many such tradit ional uses of the marjoram species were 
confirmed i n  several stud ies uti l izing both in vitro and in vivo approaches. 
Several reports ind icate that O. majorana is very rich in phenol ic 
com pounds. The h igh phenol ic content i n  Origanum has a capacity to 
scavenge free radi ca l s  to be associated with strong antioxidant activity 
[97] .  O. majorana contains  phenol ic terpenoids (thymol and carvacrol ) ,  
flavonoids (d iosmeti n ,  luteo l in ,  and apigen in ) ,  tannins ,  hydroquinone, 
phenol ic g lycosides (arbutin ,  methyl arbutin ,  vitex in ,  orientin ,  and 
thymonin)  and triterpenoids (u rsol ic  acid and oleanol ic acid)  [98]. 
O. majorana has been reported to exhibi t  sign ificant anti-microbial 
activity [99] . Several stud ies have a lso demonstrated that ethanol ic, 
aqueous extracts and the essentia l  o i l  of O. majorana could protect 
against l iver and k idney damage and genotoxicity induced by lead acetate 
[ 1 00- 1 02]. O. majorana has a lso been found to inh ibit platelet adhesion 
aggregation and secretion [ 1 03]. Furthermore, th is  plant exerts a low 
cytotoxicity on several hepatoma cel l l i nes [1 04] . It has been shown by AI 
Harbi  that an extract of O. majorana reduced the side effects induced by 
cyclophosphamide, an establ ished anticancer drug ,  without altering its 
cytotoxicity [96] . 
I n  the present study, we investigated the effect of Origanum 
majorana ethanol ic extract (OM E )  on breast cancer cel ls .  We examined 
the effects of OME on cell viabi l ity, cel l  cycle , apoptosis and tumor 
invasion and metastasis in the highly prol iferative and invasive Estrogen 
Receptor ( ER)-negative m utant p53 breast cancer cel l l ine MDA-MB-231 . 
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1 .9.2. M icroorgan isms as Source of Anti-Cancer Agents 
Many a nt i-cancer agents have been d iscovered by screening 
natural products from a wide range of microorganisms. Toxins that 
orig inal ly evolved to ki l l  competing m icroorganisms can have a variety of 
physiological  effects in animals .  In many cases, the targets of these 
com pounds are com ponents of signal transduction cascades that are 
conserved in  many species, and that have been considered novel targets 
for anticancer drug d iscovery [ 1 05] .  
Anti-tumor a ntibiotics are among the most important cancer 
chemotherapeutic agents, and include members of the anthracycl ine ,  
bleomycin ( i solated from Streptomyces verticil/us and used in  treatment of 
germ-ce l l ,  cerv ix and head and neck cancers) , actinomycin ( isolated from 
Streptomyces spp . and used to treat sarcoma and germ-cell tumors) 
[ 1 06] . Cl in ica l l y  u sefu l agents from these above fami l ies are the 
daunomycin ( isolated from Streptomyces coeruleorubidus and used to 
treat leukemia)  and related agents l ike doxorubici n ,  idarubicin ,  and 
epirubicin ( isolated from Streptomyces Pneuceticus and used in 
lym phoma, sarcomas,  breast, ovary, lung cancers) .  
Rapamycin and i ts analogs are products of Streptomyces 
hygroscopicus that have potent immunosuppressive activity. They inh ib i t  
the signal ing pathways requ ired for T-cel l  activation and prol iferation . 
Rapamycin blocks progression of the cel l  cycle at the middle-to-Iate G1 
phase in T cel l s  and B cel ls ,  and osteosarcoma and rhabdomyosarcoma 
cel l  l ines, among others [ 1 07] .  Geldanamycin is a benzoquinone 
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ansamycin natural fermentation product and inhibits the heat-shock 
protein HSP 90 [ 1 08] . 
Wortmannin i s  a product of the fungus Talaromyces wortmanni and 
inh ibits Signal transd uction pathways by forming a covalent complex with 
an active-site residue of phosphoinositide 3 kinase (PI3K), inh ibiting P I3K 
activity [1 09] . Others include a lso the peptol ides ( i .e .  dactinomycin ) ,  the 
mitosanes (such as m itomycin C) and the glycosylated anthracenone 
m ithramycin .  The anthracycl ines are among the most used anti -tumor 
anti biotics in the cl in ic and exert anti-tumor activity mainly by inh ibiting 
topoi somerase I I  [ 1 1 0] .  
Anti -cancer agents from natura l  sources exert their toxicity through 
modulation of several pathways and induction of different mechanisms of 
cel l  death and growth inh ibition . Such anti-cancer agents from natural 
sources induce apoptosis ,  necrosis, growth arrest, senescence, and 
autophagocytosis in several types of cancer. Growth inh ibition and 
induction of cel l  death are among the major objectives of anti -cancer 
therapies. 
1 .9.2. 1 .  Sa l inomycin I 
/ / 
Sal inomycin is  a monocarboxyl ic  polyether antibiotic, isolated from 
Streptomyces albus, widely used as an antibiotic to prevent 
anticoccidiosis in pou l try and as growth promoter for ruminants and swine. 
Screening for com pounds that specifically target cancer stem cells has led 
to the identification of Sal inomycin as potential anticancer agent. 
Sal inomycin was shown to ( i )  selectively induce cel l death in breast 
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cancer stem cel l s  in cell cu lture assay and ( i i )  inh ibit breast tumor growth 
i n  mice [ 1 1 1 ] .  More recent investigations have reported that Sal inomycin 
possesses a potent anticancer activity against other cancer stem cells 
such as the ALDH positive A549 lung cancer cel ls [ 1 1 2] ,  ALDH gastric 
cancer cel ls [ 1 1 3] ,  and CD1 33+ subpopulations in human CRC HT29 and 
SW480 colorectal cancer cel ls  [ 1 1 4] .  However, the mechanism of 
Sal inomycin's activity on cancer stem cel ls is yet to be elucidated . 
More recent studies reported that Sal inomycin shows efficacy 
against other human cancer cel ls including those displaying drug 
resistance [ 1 1 5] .  Sal inomycin was shown to act as a p-glycoprotein 
inh ibitor to overcome apoptosis resistance in cancer cel ls [ 1 1 6] .  Lu , et a I . ,  
20 1 0 ,  have shown that Sal i nomycin inh ibits Wnt signal ing and selectively 
induces apoptosis in chronic lym phocytic leukemia cel l s  [ 1 1 7] .  
Sal inomycin was a lso shown to induce apoptosis in human prostate 
cancer cel l s  by inducing an e levation in the i ntracel lu lar reactive oxygen 
species ( ROS)  levels and m itochondrial membrane depolarization [ 1 1 8] .  
Very recent stud ies have a lso shown that Sal inomycin inh ibits prostate 
cancer growth and migration through the induction of oxidative stress 
[ 1 1 9] .  
A com bination treatment using Sal inomycin with gemcitabine has 
proven to be more effective than ind ividua l  drugs against pancreatic 
cancer cel l s  [ 1 20]. I t  appears that Sal inomycin sensitizes cancer cel ls to 
the effects of etoposide and doxorubicin treatments by enhancing 
apoptosis ,  increasing DNA damage and reducing the level of p2 1 protein 
[ 1 2 1 ] . I ndeed , Sal inomycin sensitizes radiation-treated cel ls by inducing 
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G2 arrest and causing DNA damage [ 1 22]. More recently, Sal inomycin 
was reported to sensitize cancer cel ls to antimitotic drugs ( pacl i taxe l ,  
docetaxel , v inblastin and colch icine)  by enhancing apoptosis as well as 
preventing G2 arrest [ 1 23]. 
Despite the recent find ings ,  the mechanisms underlying the 
anticancer activity of Sal i nomycin are sti l l  poorly understood . In the 
present study, we have investigated the effect of Salinomycin on MCF-7,  
T470 and the trip le negative M DA-M B-23 1 human breast cancer cel l 
l i nes. 
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SPEC EIFIC AIM S O F  THE STUDY (OBJ ECTIVES) 
1 .  Test ing the efficacy of Origanum majorana plant  extract and 
Sa l i nomyc i n  against d ifferent types of human breast cancer in vitro 
(cancer cel l  l i nes) and i n  vivo (ch ick embryo tumor growth and 
metastas is  assay). 
In this study, the effects of th is  plant extract and th is com pounds on cel l  
v iabi l ity, apoptosis, m igration and invasion in vitro and the progression 
and metastasis of human sol id breast tumors in vivo were evaluated . 
2. Identification of downstream b iomarkers associ ated with response 
to the treatment with selected active plant extracts . 
B ecause most anticancer drugs are known to a lter gene expression , we 
examined the effects of the O. majorana extract and Sal i nomycin on the 
expression of pathways (apoptosis ,  cel l  cycle . . .  ) - specific genes in several 
breast cancer cel l  l ines using western blot, immunofluorescence and RT­
peR a na lysis. 
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CHPATE R  2 :  MATERIALS AND M ETHODS 
2 . 1 .  Preparation of the Origanum majorana Ethanol ic  Extract 
Origanum majorana commonly known as "marjoram" and used as a 
cu l inary herb was obtai ned from a private commercia l  farm located in  the 
Tyre region of Lebanon . All necessary permits were obtained for the 
harvesting of the leaves. 5 .0  g of the dried leaves were ground to a fine 
powder u sing a porcela in mortar and pestle. The powder was suspended 
in 1 00 m L  of 70% absolute ethanol and the mixture was kept in the dark 
for 72 hours at 4°C in  a refrigerator without stirring . The mixture was then 
fi l tered through a g lass sintered funnel and the filtrate was evaporated 
us ing a rota-vapor at room temperature.  The green residue was kept 
u nder vacuum conditions for 2-3 hours and its mass was recorded . 
2.2 .  Ce l l  Cu lture and Reagents 
Human breast cancer cel ls  MOA-MB-23 1 and MCF-7 were 
ma intained i n  OMEM ( H yclone ,  Craml ington , UK) and the MOA-MB-23-
GFP u sed i n  this study was ma intained as previously described [ 1 24] . The 
T47-0 breast cancer cel l s  were mainta ined in RPMI  1 640 ( Hyclone). Al l  
m edia were supplemented with 1 0% fetal bovine serum and 1 00U/ml 
penic i l l in/streptomycin ( invitrogen) .  HUVECs ( I nvitrogen ,  Carlsbad , CA, 
USA) were mainta ined in M E M  1 99 supplemented with 20% FBS, 
penici l l i n/streptomycin ,  2 mM L-g lutamine,  5U/ml heparin and 50 IJg/m l 
endothel ia l  cel l  growth supplements (BO Biosciences, Bedfrord , MA, 
USA) .  Sal i nomycin and 4-Hydroxy-Tamoxifen were purchased from 
Sigma-Aldrich (Sa int-Quent in Fal lavier; France). Antibodies for p21 
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( 55643 1 ) ,  PARP ( 556494) were obtained from BD Pharmingen . 
Antibodies for phosphor-H2A.X (ser1 39) (07-1 64) ,  acetyl-Histone H3 (06-
599) ,  acetyl -Histone H4 ( 06-866) ,  phosphor-H istone H3 ( ser1 0) (05-1 336), 
P53 ( E26,  04-24 1 ) , Cycl in B1 (05-373) and cycl in D1 (04- 1 1 51 )  were 
obtained from Mi l l ipore.  Antibodies for survivn (sc- 1 779) ,  ICAM-1 (sc- 1 07) ,  
[3-actin (C4, sc-47778) ,  goat anti-mouse IgG-HRP ( sc-2005) and goat anti­
rabbit IgG-HRP (sc-2004) were obtained from Santa Cruz Biotechnology, 
I nc .  Antibod ies to E-cadherin (ab1 51 48), TN F-u (ab9739) and uPAR (ab 
1 03791 ) from Abca m .  Antibodies to p27 (3686) ,  N F-kB p65 (3034) ,  p lKB-a 
( ser32) (2859) from Cell Signal ing (Cel l  Signal ing Technology, I nc . ,  
Danvers, MA,  USA). AlexaFluor 488 goat anti -rabbit IgG ( H+L) (A1 1 008) 
and AlexaFluor 594 goat anti-mouse IgG (H+L) (A1 1 005) were obta ined 
from Invitrogen . 
2.3 .  Ce l lu lar  Viabi l ity 
Cel ls  were seeded in trip l icate in 96-wel l  plates at a density of 
5 000 cel l s/wel l .  After 24 hours of cu lture ,  cel l s  were treated with , 
increasing concentrations of Sal i nomycin or OME and incu bated for the 
ind icated time periods. Control cel ls were exposed to DMSO cel ls (in case 
of Sal inomycin )  at a concentration equivalent to that of the Sali nomycin ­
treated or equal  volume of 70% ethanol ( in  case of OM E). I n  combination 
experiments, MCF-7 and MDA-MB-231  cel ls  were subjected to 
sim ultaneous treatment with 20 IJM 4-hydroxy-tamoxifen A and 1 IJ M 
frondoside A, respectively ,  p lus DMSO or increasing concentrations of 
Sal inomycin for 48 hours. The effects of Sal inomycin ,  alone or in 
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combination ,  on cel l viabi l ity was determined using a CeliTiter-Glo 
Luminescent Cel l Viabi l ity Assay (Promega Corporation , Madison , USA), 
based on quantification of ATP,  which signals the presence of 
m etabol i ca l ly  active cel ls .  Luminescent signals were measured using a 
B erthold F B  1 2  Luminometer. The Data were presented as proportional 
viab i l i ty ( % )  by comparing the treatment group with the untreated cel ls ,  the 
viabi l i ty of which is assumed to be 1 00%. 
Cel l  viabi l i ty was a lso assessed using Trypan B lue Exclusion 
Assay.  Cel ls were plated onto 24-wel l  plates (20 x 1 04 cells/wel l ) .  The day 
of the treatment the cel ls were counted to estimate the approximate 
number of cel l s  per wel l .  Fol lowing Sal inomycin treatment at ind icated 
tim es ,  cel ls were trypsinized , pel leted by centrifugation and resu spended 
in serum free DMEM and sta ined with trypan blue. Dead (stained blue) 
and l ive (unsta ined )  cel ls were counted on a Neubauer Hemacytometer. 
Three independent assays were performed in trip l icate, and results were 
reported as the means ± SEM.  
2 .4. Caspase 3/7, 8 and  9 activit ies 
M DA-MB-231 , MCF-7 cel ls were seeded at a density of 5 ,000 cel ls 
1 wel l  into a 96-wel l  plate in  tripl icate and treated with the drugs for 24 
hours and 48 hours. Caspase-3/7 , 8 and 9 activities were measured using 
a l um in escent Caspase-Glo 3/7, Caspase8 and Caspase 9 assay kits 
( P romega Corporation , Madison,  USA) fo l lowing the manufacturer's 
i n structions. Caspase reagents were added to trip l icate in the 96 wel ls. 
The p late was mixed on an orbital shaker and incu bated for 2.5 hours at 
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room temperature in the dark. A lum inescent signal was measured as 
described above. 
2 .5. Senescence Associated-�-Galactosidase (SA-�-gal )  Sta in ing 
2 . 5  x 1 05 M DA-MB-23 1 cells were cultured in 60mm culture dishes 
for 24 hours and then exposed to Sal inomycin 1 O�M or DMSO for 96 
hours.  Treatment and control cel ls  were then washed in PBS, and fixed 
with 2% formaldehyde/ 0 .2% glutaraldehyde for 5 min utes at room 
temperature. The SA-!3-ga l  stain ing was conducted as previously 
described [ 1 25] 
2.6 . F low Cytometric Analysis of Cel l  Cycle 
M DA-M B-23 1 cel l s  ( 1 .8 X1 06) were seeded in  1 00mm culture 
d ish es and cultured for 24 hours before the addition of either OME extract 
or Sal i nomycin at the con centrations indicated in the resu lts part. After 
incubation ,  cel ls  were harvested, washed twice with ice-cold PBS , 
resuspended in 500�1 PBS,  fixed with an equal volume of 1 00% ethanol 
and incubated for at least 1 2  hours at -20°C. Cel ls were then pel leted , 
washed twice with PBS, permeabi l ized in 0 . 1  % Triton X-1 00/PBS for 1 5  
m i nutes on ice, pel leted and then resuspended in PBS contain ing 40�g/m l 
propid ium iodide and 25�g/ml RNase A, at 37°C for 30 minutes. Cells 
were analyzed using BD FACSCanto I I  (Becton Dickinson).  Data 
acq u isition was conducted u sing FACSDiva 6. 1 software. The percentage 
of cel ls in the G1 , S and G2/M phases were determined using the FlowJo 
software. 
28 
2 .7 .  Quantification of Apoptosis by Annex in  V IPropid ium iodide (PI )  
Sta i n i ng 
DMSO and Sal inomycin-treated MDA-MB231 ( 1 .8 x 1 06) cel ls 
grown i n  1 00mm cu lture d ishes were harvested by trypsin release and 
washed twice with ice-cold PBS.  Apoptotic cel l death was determined 
using the BD F ITC Annexin V Apoptosis Detection Kit I I  (BD Biosciences) 
according to the manufactu rer's instructions. Cel l  samples were analyzed 
using the BD FACSCanto I I  (Becton Dickinson) .  
2.8. Immunofluorescence Stai n i ng 
M DA-M B  231  cel l s  (4  X1 04) were grown on 4 well labtek chamber 
sl ide ( Becton Dickinson) for 24 hours, and then treated with veh icle as 
control or either O M E  extract or Sal inomycin for 24 hours at the 
concentrations indicated in the results come later. Cel ls were then fixed in  
1 0% formal in solution (4% paraformaldehyde) (S igma-Aldrich ; Saint-
Quentin Fal lavier, France)  for 5 m inutes at room temperature fol lowed by 
permeabi l ization in PBS contain ing 0 . 1  % Triton X-1 00 for 5 minutes at 
room temperature. Cel ls were then washed three t imes with PBS, blocked 
with 5% non-fat dry m i l k  in PBS for 30 minutes at room temperature and 
then incubated with the primary antibody d i luted in  1 % non-fat dry 
m i l k/PBS overnight at 4°C. Fol lowing incubation, cel ls were washed three 
times with PBS and incu bated for 1 hour at room temperature in the 
presence of rhodamine-conjugated or fluorescein-conjugated secondary 
antibody di luted at 1 :200 in  1 % non-fat dry mi lk/PBS.  After washing with 
PBS cel ls were mounted in F luorosch ield with DAPI (Sigma-Aldrich ) and , 
examined under N ikon Ti U fluorescence microscope. 
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2.9 .  Colony Format ion Assay in  Soft Agar 
Assays were performed in  six-wel l  plates. The lower (base) layer 
consisted of 1 ml 2 .4% Noble Agar. The base layer was overlaid with a 
second layer consist ing of 2 .9  ml  growth mediu m ,  0 .3% Noble Agar, and 3 
x 1 04 M OA-MB-23 1 cel ls .  Agar at 50aC was m ixed with the medium at 
3rC, plated , and left to set for 1 0  minutes. Growth medium was then 
added and plates incubated at 37°C. Cells were a l lowed to grow to form 
colonies for 1 4  days before treatment with either Sal inomycin or OME 
extract. Colonies were a l lowed to grow for one more week. Fol lowing 
treatment, plates were washed twice with PBS and then colonies were 
fixed with 1 0% ice-cold m ethanol for 1 0  min and washed once with PBS. 
Colonies were a l lowed to sta in  for 1 hour  in  a solution containing 2% 
Giemsa. The size of the colonies was measured , using a microscope 
( 1 0X) and the colony size was categorized as Large ( >400 iJm), medium 
( 200-400 I-'m), or smal l  ( 50-200 iJm) .  Colony sizes were expressed as a 
percentage of tota l counted colonies and then compared to the vehicle 
treated controls ( OMSO).  The experiment was repeated three times. 
2 . 1 0. Nuclear and whole Cell Extract and Western Blot Analysi s 
Cel ls ( 1 .8 x 1 06) were seeded in  1 00mm culture d ishes and 
cultured for 24 hours before the addition of various concentrations of 
either Sal inomycin or O M E  extract. For whole cell Iysates, fo l lowing 
incubation , cel ls  were washed twice with ice-cold PBS, scraped , pelleted 
and lysed in R I PA buffer (89900, Pierce) supplemented with a 
protease/phosphatase inh ibitor cocktai l  ( 1 861 281 , Pierce). After 
incubation for 30 m i n utes on ice, cel l Iysates were centrifuged at 1 4,000 
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rpm for 20 m inutes at 4°C . Nuclear extract were prepared from vehicle-or 
O M E-treated M OA-MB-23 1 cel ls using the NE-PER extraction reagents 
(Thermo Scientific, Rockford , I l ,  USA) .  The protein concentration of the 
Iysates was determ ined using BCA Protein Assay Kit (23225, Thermo 
Scientific) and the Iysates were adjusted with lysis buffer. Al iquots of 25 
�g of tota l cel l lysate were resolved onto 1 0-1 2% SOS-PAGE. Proteins 
were transferred to n itrocel lu lose membranes (880 1 8, Thermo Scientific) 
and b locked for 1 hour at room temperature with 5% non-fat dry milk in 
TBST (TBS and 0 .05% Tween 20) .  I ncubation with specific primary 
antibodies was conducted in  a blocking buffer overnight at 4°C. 
Horseradish peroxidase-conjugated anti- lgG was used as secondary 
a ntibody,  Immunoreactive bands were detected by ECl chemi luminescent 
substrate (32209, Thermo Scientific). Also when needed , membranes 
were stripped in a Restore Western B lot Stripping Buffer (2 1 059, Thermo 
Scientific) according to the manufacturer's instructions. 
2 . 1 1 .  Wound Hea l i ng M i g ration Assay 
M OA-M B-23 1  cel ls were grown in  six-well t issue cultu re d ishes unti l 
confluence. A scrape was made through the confluent monolayer with a 
steri le  plastic pipette tip of 1 mm diameter. Afterwards, the d ishes were 
washed twice with PBS and incubated at 3rC in  fresh OMEM 
complemented with 1 0% fetal bovine serum in the presence or absence of 
the ind icated concentrations of OME.  At the bottom side of each dish, 
th ree arbitrary p laces were marked where the width of the wound was 
m easured with an inverted m icroscope (objective x 1 0) .  Wound closure 
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was expressed as the average ± SEM of the difference between the 
m easurements at time zero and a 1 0  hours' t ime period . 
2.1 2. M i g ration Chamber Assay 
5 x 1 04 cel ls  were seeded in  the upper chamber, HTS Multiwel l  
I nsert System (BO Biosciences, Frankl in Lakes, NJ, USA), in  serum-free 
m ed iu m ,  with or without OME and migration assay,  A serum-containing 
medium was added to the lower chamber to act as a chemotactic 
attractant. After 6 hours of i ncubation , cel ls were washed with PBS, and 
fixed with forma ldehyde. Cel ls were then stained with 1 % crystal violet for 
1 0  m i nutes. After washing with PBS, cel ls from at least 5 d ifferent random 
fields were counted under a m icroscope. 
2. 1 3. Aggregation Assay 
Growing cel ls  were detached using a 2mM EDT A in  calcium 
m agnesium-free PBS (CMF-PBS).  A cel l suspension of 1 x 1 06 cel ls/ml 
was al iquoted into microcentrifuge tubes, washed with PBS, resuspended 
in a 1 ml culture media and incu bated with or without OME on a rocker for 
1 hour at 3rC. Cel ls were then fixed with 1 % formaldehyde and pictures 
taken under an i nverted m icroscope (Olympus IX7 1 ). Aggregation was 
calculated as previously reported [ 1 26] using the fol lowing equation: % 
aggregation= ( 1 -NUNc) x 1 00 ,  where Nt and Nc represent the number of 
s ing le cel ls  in  treatment and untreated groups, respectively. 
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2 . 1 4. Adhesion Assay 
Adhesion of M OA-M B-23 1 to H UVECs was performed as 
previously described [ 1 27] with minor modifications.  Cel l  culture plates 
were coated with col lagen and HUVECs grown to confluent monolayers. 
TN F-a (25ng/m l) was added for 6 hours to stimu late H UVECs prior to the 
addition of M OA-MB-23 1 cel ls .  MOA-MB-23 1  transfected with Renifla 
Luciferase were resuspended in H BSS conta in ing a 1 % BSA at a 
concentration of 2x1 05 cel ls/m l .  1 50 1-1 1  of this cel l  suspension was added 
to the u pper chamber conta in ing confluent H UVECs in  the absence or 
presence of O M E .  After 1 hour, unattached cel ls were removed by gently 
washing the plates three t imes with PBS. Adherent cel ls  were lysed using 
a luciferase lysis buffer (Promega, Madison,  W I ,  USA) and l ight un i ts were 
m easured . 
2 . 1 5. M atr ige l I n vasion Assays 
The invasiveness of the MOA-MB-23 1  cell was treated with the 
ind icated concentrations of OME and tested using a BO Matrigel I nvasion 
Chamber (8-l-Im pore size: BO B iosciences, Bedfrord , MA, USA). M OA­
MB-231 ( 1  x 1 05) cel l s  were p laced in 0 .5  m L  of med ia conta in ing veh icle 
or the ind icated concentrations of OME were seeded into the upper 
chambers of the system. The bottom wel ls in the system were fi l led with 
OMEM complemented with 1 0% fetal bovine serum as a chemo-attractant 
and then incubated at 3rC for 24 hours. Non-penetrating cel ls were 
removed from the upper surface of the fi lter with a cotton swab. Cel ls that 
have migrated through the matrigel were fixed with 4% formaldehyde, 
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stained with DAPI and counted in  6 random fields under a microscope. 
For quantification , the assay was done in  dupl icate then and repeated 
three t imes. 
2 . 1 6. Meas u rement of Matrix Metal loprote inases by ELISA 
Cel ls were seeded in 6-wel l  plates i n  the absence of vehicle or 
OME for 24 hours.  The conditioned med ium was col lected and the levels 
of M M P-2 and M M P-9 secreted were determi ned using immunoassay kits 
( I nvi trogen ,  Camari l lo ,  CA, USA) . The experiments were repeated three 
t imes and the average of the three means was represented as ± SEM.  
2. 1 7. Gelat in  Zymography 
G elat in zymography was conducted as  previously described [ 1 28].  
M DA-MB-2 3 1  ( 2 . 5  x 1 06) cel ls were incubated in  serum-free OM EM for 24 
hours in the presence of vehicle or O M E  ( 1 50 and 300 \Jg/mL). The 
conditioned med ium was col lected , concentrated and 30 \Jg of total 
protein was resolved in 1 0% polyacry lamide gel contain ing 0 . 1  % gelati n .  
After electrophoresis ,  the gel was washed for 1 hour in  2 .5% (v/v) Triton 
X-1 00 to remove SDS and then incubated overn ight at 3rC in 50 m M  
Tris-HCI ( p H  7 .5) ,  1 50 mM NaCI , 0 .5  m M  ZnCI2 a n d  1 0  mM CaCI2 to a l low 
proteolysis of the gelatin substrate. Bands corresponding to activity were 
visua l ized by n egative sta in ing using 0 .5% Coomassie bri l l iant blue R-250 
( Bio-Rad,  Hercules, CA, USA). Representative results from two 
i ndependent experiments are shown. Densitometry was conducted using 
I mageJ software and the band density was normal ized to the non-specific 
band sta in ing on the gel . 
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2. 1 8. Quantitative Immunoassay for Human Vascular Endothe l ia l  
G rowth Factor (VEGF) 
M DA-MB-231  cel ls  ( 1 .5 x 1 05) were seeded in  24-wel l  plates. The 
condit ioned m ed ium was col lected and the level of VEGF measured using 
a VEGF Enzyme-Linked Immunosorbent Assay Kit ( R&D Systems, 
M inneapol is ,  M N ,  USA. Assays were performed in trip l icate and three 
i ndependent experiments were conducted . The data is presented as mean 
values ± S E M .  
2 . 1 9. Quantification of N itrate/N itrite Prod uction 
The amount of n itrate/n itrite production was determ ined with a 
colorim etric EL ISA Kit (Cayman Chemica l ,  Ann Arbor, Michigan ,  USA), 
wh ich is based on the Griess reaction . The value of n itrate/nitrite 
presented is the total value measured in the presence of cel ls  m inus the 
value determ ined from the media a lone in the absence of any growing 
cel ls .  
2.20.  Lucife rase Activity 
M DA-M B-23 1 cel l s  were seeded in  1 2-wel l  plates the day before 
transfection .  Cel ls were then transfected with the E-cadherin Luciferase 
Reporter Expression Plasmid [ 1 29] using Lipofectamine 2000 (L ife 
Technologies, I nc. Grand I sland, NY, USA). Cel ls were al lowed to recover 
for 4 hours after transfection in OPT I -MEM ( Life Technolog ies, Inc . ,  Grand 
Is land,  NY, USA) which was then rep laced with a complete medium.  
Luciferase activity was measured u sing Dual  Luciferase Reporter Assay 
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System (Promega,  Madison, W I ,  USA). Renilla Luciferase reporter was 
u sed as  an internal  contro l ,  to which fi refly luciferase values were 
normal ized . Experiments were repeated three t imes and the average of 
the three means was represented ± SEM.  
2.2 1 . Transendothe l i a l M igrat ion Assay 
Transendothel ia l  m igration of M DA-MB-231 th rough H UVEC was 
conducted as previously described [ 1 30]. Transwell fi lters were coated 
with col lagen and a l lowed to dry overn ight. HUVECs (2 X 1 05/wel l )  were 
then seeded onto the rehydrated membrane and a l lowed to grow unti l  a 
confluent monolayer was formed . TN F-a (25ng/ml )  was added for 6 hours 
to stim ulate H UVECs. Then, M DA-M B  -23 1 cel ls ( 1  x 1 06) were loaded on 
top and i ncubated overnight i n  the absence , or presence, of OME.  Cel ls 
on the u pper chamber were removed with a cotton swab, whereas MDA­
M B-23 1 on the bottom were sta ined and quantified as previously reported 
[ 1 30]. 
2.22. R N A  Extract ion and RT -peR 
Total RNA from veh icle- or O M E-treated MDA-MB-23 1 cel ls  were 
prepared using Trizol reagent ( Life Technologies, Inc .  Grand I sland,  NY, 
USA) .  The RNA expression of MMP-2 and MMP-9 was determined by RT­
PCR.  RT-PCR was performed using the Qiagen OneStep RT-PCR Kit 
( Qiagen,  H ilden , Germany).  Equal amounts of RNA ( 500 ng) were used as 
templates in each reaction .  The sequences of specific primers were as 
fol lows: M MP-2 sense, 5'-TCTCCTGACATIGACCTTGGC-3', and 
antisense: 5'-CAAGGTGCTGGCTGAGTAGATC-3' ;  MMP9 sense, 5'-
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TTGACAGCGACAAGAAGTGG-3', and antisense, 5'­
CCCTCAGTGAAGCGGTACAT-3', GAPDH sense, 5'­
G G CCTCCAAGGAGTAAGACC-3', and antisense 5'­
AGGGGTCTACATGGCAACTG-3'. The PC R products were separated by 
1 .5% agarose gel and visual ized by eth id ium bromide sta in ing .  
Representative resu lts from two i ndependent experiments are shown . 
2.23.  C h ick Embryo Tumor Growth and Metastas is Assay 
The chick embryo tumor growth assay was performed as previously 
described [ 1 3 1 ]  with sl ight mod ifications.  According to French legislation , 
no  eth ical approval is needed for scientific experim entation using 
oviparous embryos (decree n020 1 3-1 1 8 , February 1 ,  20 1 3; art .  R-2 1 4-88) .  
Th is  work was done under an ima l  experimentation permit  N°381 029 
issued to Jean Vial let and an imal  experimentation permit N° 
B385 1 6 1 000 1 i ssued to Institute Albert Bonniot. Fertilized White Leghorn 
eggs ( Societe Franyaise de Production Agricole, St. Brieuc, France), were 
i ncubated at 38°C with 60% relative humid ity for 1 0  days. At stage E 1 0 ,  
the chorioal lantoic membrane (CAM) was dropped b y  d ri l l ing a smal l  hole 
th rough the eggshell into the a i r  sac and a 1 cm2 window was cut in the 
eggshel l  above the CAM .  Cultu red M DA-MB-23 1 -GFP were detached by 
trypsin ization , washed with complete medium and suspended in serum 
free D M E M .  A 50 IJ I  inocu lum of 1 X 1 06 MDA-M B-23 1 -GFP cel ls was 
added onto the CAM of each egg (eggs were randomized in 4 groups of 
1 5) .  One day later, tumors that began to be detectable were treated every 
second day at E 1 1 ,  E 1 3, E 1 5 and E 1 7 by dropping 1 00 IJ I  of either OME 
( 300 \Jg/m L or 450 IJg/mL), colch icine (2\JM) or 0.02 % ethanol (vehicle) in 
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PBS onto the tumor. At E 1 9  the upper portion of the CAM was removed , 
transferred i n  PBS and the tumors were then careful ly cut away from 
normal CAM tissue and weighted . I n  paral le l ,  a 1 cm2 portion of the lower 
CAM was col lected to eva luate the number of nodules, contain ing GFP­
expressing cel ls .  The fluorescent nodule were visual ized in situ using 
whole mounts of tissue fixed in 4% formaldehyde in PBS and flattened 
between a hol low glass sl ide and a th ick coversl ip .  In order to number the 
nodules,  a thorough and complete visual scan of the p iece of the lower 
CAM was done using a fl uorescent microscope. Chick embryos were 
sacrificed by decapitation .  
2.24. Stati stical Analysis 
Results were expressed as means ± SEM of the number of 
experiments. A p value of < 0 .05 was considered statistical ly sign ificant. 
Student's t-test was used to detect the difference between the two values. 
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CHAPT E R  3 :  RESU LTS AND DISCU SSION 
Part I .  Anti -breast cancer activ i ty of Sa l i nomyc in  
3 . 1  Growth I n h i b itory Effect of Sal inomycin  o n  M OA-M B-.231 , MCF-7 
and  T470 Breast Cancer Cel l  L i nes 
To examine the anticancer activity of Sal inomycin on breast cancer 
cel l s, we first measured the effect of various concentrations of 
Sal inomycin ( 1 ,  2 . 5 ,  5, 1 0 , 25 and 50 �M)  on the prol iferation of three 
different breast cancer cell l i nes (MOA-MB-23 1 ,  MCF-7 and T470).  The 
data obtained is summarized in figure 1 .  Our results show that exposure 
of the three cel l  l ines to Sal inomycin decreased cel lular viabil ity in 
concentration and in a time-dependent manner. However, the growth 
inh ibitory effect of Sal inomycin appears to be more pronounced in MCF-7 
and T470 than in  M OA-MB-23 1 .  The ICso ( producing half-maximal 
inh ibition)  at 24 hours was approximately 40 �M for the MCF-7 and T470 
(fig .  2 and 3) wh i le the same concentration gave only about 35% inhibition 
of proliferation in the M OA-MB-231 cel ls (fig .  1 ) . Fol lowing 48 hours of 
treatment, I Cso was 1 5  � M  for the MCF-7 and T470 (fig .  2 and 3 )  and 
approximately 35 �M for the MOA-MB-231  cel ls .  Maximal inh ibition (90%, 
P<0.05) of cel l  growth was observed with 50�M for the MCF-7 and T470 
cel l  l ines.  The same concentration gave approximately 70% inh ibition of 
prol iferation of the M OA-MB-231  cell l ines (fig . 1 ) . Taken together, our data 
show that Sal inomycin inh ibits cell growth of breast cancer cel l  l i nes in a 
concentration and t ime-dependent manner and that MCF-7 and T470 
exhibit a greater sensitivity to Sal inomycin com pared to the MOA-MB-231  
cel l s. 
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Figure 1 .  I nh ibit ion of Cel lu lar  Viabi l i ty of MDA-M-231  Cel ls by 
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Figure 2 .  Inh ibition of Cel lu lar Viabi l ity of MCF-7 Cel ls by Sal inomycin .  
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Figure 4 .  Cel l  Viabi l ity of MOA-MB-23 1 Cel ls in Response to Various 
Concentrations of Sal inomycin Using Trypan Blue Exclusion Dye Assay. 
4 1  
We next focused only on the h igh ly prol iferative and invasive 
Estrogen Receptor (ER)-negative, mutant p53 breast cancer cell l ine 
MDA-MB-23 1 to investigate the mechanism by which Sal inomycin 
decreased cel l viabi l ity. 
In order to d ist inguish between cel l  death and the possible growth 
arrest effects of Sal inomycin ,  cel l  v iabi l ity of the MDA-MB-231 cel ls was 
monitored by using the trypan blue exclusion dye assay at 24 and 48 
hours after the Sal i nomycin treatment. As it i s  shown in Figure 4 ,  Trypan 
B lue Assay a lso showed a dose- and t ime-dependent decrease in  viabi l ity 
in Sal inomycin-treated cel ls  when com pared to the control cel ls .  
However, a closer look to the number of viable (Trypan Blue Negative) 
cel ls  counted in each treatment, revealed that the number of cel ls  after 
treatment with 2 .5 ,  5 and 1 0  IJM did not sign ificantly change at 24 and 48 
hours and moreover, was com parable to the number of cel ls counted at 
the day of treatment (Table 1 )  with a very low percentage of cel l  death 
(Trypan B lue  Positive) suggesting that prol iferation of the MDA-MB-23 1 at 
these concentrations is inh ibited and cell death is min imal  (Table 1 )  . 
I n terestingly,  at h igher concentrations of Sal inomycin (25 and 50 IJM) ,  the 
number of viable M DA-MB-23 1 cel l s  showed a steady decl ine after 24 and 
48 hours indicative of cel l  death. The number of viable cel ls compared to 
the day of treatment, dropped to 58% and 42% at 25 IJM and to 48 and 
28% at 50 IJ M .  
Comparative analysis of cel l  v iabi l ity between CeliTiter-Glo and 
Trypan B lue Exclusion assay shows that cel l  viabi l ity data obta ined by 
Cel lTiter-G lo and trypan blue exclusion assays are not perfectly super-
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imposable (fig . 5 and 6) .  As a matter of fact, the same concentration of 
Sa l inomycin gave sl ightly different I C50 between Trypan Blue Exclusion 
and Cel lTiter-Glo assay. 
I I 
Viable cel ls ( number and 
Sa l i nomyc i n  Dead cel ls ( n um ber a n d  %) %) 
(JJM )  
24 hours 48 hours 24 hours 48 hours 
641 22 1 43055 
Control 589 ( 1 .0%) 231 1 (2%) (1 00%) ( 1 00%) 
2 .5  I 1 078 (2.0%) 822 (76%) 63688 (45%) 
5 I 1 844 (4.0%) 2700 (4.0%) �6877 (73%) 55400 (39%) 
1 0  2244 (6%) 3244 (7%) 39322 (61 %) 43844 (31 %) 
25 AA78 ( 1 7  fO) 6978 (27%) 23288 (36%) 1 9377 (41 %) 
50 21 56 ( 1 2%) i 1 2089 (50%) 1 6244 (25%) 1 1 333 (8%) 
* N umber of ce l ls  counted at the day of treatment (Oh)  approximately 
39000 
Table 1 .  Viabi l ity of MDA-MB-23 1 Cel ls in Response to Sal inomycin 
Determined by Trypan Blue Exclu sion Assay. 
4 3  
1 20 
M DA- M B-231 _ CeliTiterGlo 
(24 hours)  
� Trypan Blue 
Q) 1 00 =- :3  0 -.b ID C C 80 o co 0 0.  
..... c:-� �  0" ",  60 � >  
.� .2 
j5 "  co .... - Q) > .� 40 
= t:  Q) -
U Q) U 20 
0 
0 2 .5  5 1 0  25 50 
Sa I inomycin (IJM) 
Figure 5 .  Cel l  Viabil ity of  the M DA-MB-231  Cel ls  in  Response to 
Sal inomycin After 24 Hours Determined by Trypan B lue Exclusion Dye 
and Cel iTiter-Glo Assays. 
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Figure 6 .  Cell Viabi l ity of  M DA-MB-231  Cel ls in Response to Sal inomycin 
After 48 Hours Determined by Trypan Blue Exclusion Dye and CellTiter-
G lo Assays. 
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3 .2  Sal i nomyc in  Ind uces Morphological  Changes i n  MDA-MB-231 
Ce l ls  
Light microscopy observation of  Sal inomycin-treated MDA-MB-231 
cel ls revealed morphologica l  changes induced by this compound . As 
shown in figure 7 ,  MDA-MB-23 1  cel ls treated with concentrations of 
Sal inomycin 5 ,  1 0  and 25 �M,  underwent morphological changes 
characterized by a loss of their epithel ial  morphology visible after 24 hours 
of treatment. These cel l s  appeared dispersed and exhibited fibroblast- l ike 
morphology with fi lopod ia- l i ke extensions and central nuclei .  However, the 
fibroblast-l ike morphology observed in these cel ls is not due to an 
epithel ia l-mesenchymal transition ,  since no changes in levels of vimentin 
and E . cadherin proteins was detected by a western blot analysis (fig .  8) 
and immunofluorescence (fig .  9). Interestingly, a subpopulation of MDA­
M B-23 1  cel ls treated with low concentration of Sal inomycin exhibited a 
senescence-l ike phenotype characterized by cel l  size increase and 
flattening shape compared to the control cel ls  (fig .  7 arrows). At higher 
concentrations of Sal inomycin (25 and 50�M),  cel ls  appeared smaller and 
rounded, characteristic of cel ls  undergoing apoptosis .  Strikingly, lower 
concentrations of Sal inomycin up to 1 0 �M did not lead to further change 
in cel l morphology nor to cell density after 72 hours exposure to 
Sal inomycin (fig 1 0 ). I n  contrast higher concentrations (25 and 50) led to 
fewer cel ls on the p late and further rounded cel l s. These morphological 
changes seem to be specific to MDA-MB-2 3 1  cel ls ,  since no obvious 
changes were observed in the MCF-7 and T47D cel l  l ines.  
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Figure 7 .  Morphologica l  Changes Observed in  the MDA-MB 231 Celis 
After 24 Hours of Treatment with Various Concentration of Sal inomycin .  
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Figure 8. Western Blot Analysis of Vimentin and E-cadherin Expression in 
Sal inomycin Treated M DA-MB-23 1 Cel ls .  
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Figure 9 .  I m m unofluorescence Sta in ing for Vimentin in Sal inomycin 
Treated M DA-MB-231  Cel ls .  
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Figure 1 0 . Morphological Changes Observed in the MDA-MB 231  Cel ls 
After 72 Hours of Treatment with Various Concentrations of Salinomycin .  
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3.3 Sa l i nomyc i n  Induces Apoptos i s  i n  MDA-MB-231 Ce l ls  
Sal inomycin was reported to mediate apoptosis in  many human 
cancer cel l s  [ 1 1 5] .  Therefore , we investigated whether the observed 
inh ib i tion of cel l  viabi l ity upon Sal inomycin treatment in the M DA-MB-23 1 
cel ls  was associated with the induction of apoptosis. Flow cytometry 
ana lys is of Annexin V and Propid ium Iodide (P I )  stain  was used to 
determ ine the percentage of apoptotic cel ls induced by Sal inomycin after 
24 hours of treatment. Treatment with 5 and 1 0  !JM Sal inomycin did not 
lead to a change in the early stage (Annexin v+/pr)  nor in the late stage 
a poptotic cel ls (Annexin V+/pn/necrotic cel ls suggesting the absence or 
m in ima l  cel l  death in these popu lations (fig .  1 1 ) . However, h igher 
concentration s  (25 !JM) led to an increase in  both early and late 
a poptotic/necrotic cel l  population . 
I m m unofluorescence m icroscopy was a lso used to confirm 
a poptosis in the Sal inomycin-treated cel ls .  Fluorescence sta ining of 
Annexin V was detected only in cel l s  treated with 25 !JM of Sal inomycin 
(fig . 3B ,  lower panel ), whi le no Annexin V stain ing was detected at a 
concentration of 1 0  jJM (fig .  1 2 , m iddle panel ) or lower concentrations, 
fu rther confirm ing the absence of a poptosis in  these cel ls .  Interestingly, 
the proportion of dead cel ls  detected by Trypan Blue Exclusion Assay at 
25 \-lM was h igher than the proportion of apoptotic cel ls detected by flow 
cytom etry suggesting that a poptosis m ight account only partly for the cel l 
death induced by high concentrations of Sal inomycin .  
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Figure 1 1 .  Sal inomycin induced apoptosis in the MDA-MB-23 1 cel ls .  
Annexin V binding was carried out using Annexin V-FITC Detection Kit. 
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Figure 1 2 . Immunofluorescence Stain ing for Annexin V-FITC in 
Sal i nomycin Treated M DA-MB-231 Cel ls .  
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Apoptosis was further examined by measuring Caspase 3/7 
activation in MDA-MB-231 cel ls treated with low ( 1 0jJM)  or high 
concentrations (50jJM)  of Sal i nomycin after 24 and 48 hours of treatment. 
Consistent with Annexin V sta in ing ,  Caspase 3/7 activation was detected 
in  cel ls treated with 50jJ M  but not in cel ls treated with 1 0jJM (fig. 1 3) .  
Furthermore, as figure 1 4  shows, PARP cleavage occurred only in cel ls 
treated with h igher concentrations of Sal inomycin (25 and 50jJM), whi le no 
cleaved PARP is detectable at lower concentration of Sal inomycin (5  and 
1 OjJM) .  The lack of Caspase 3/7 activation and cleavage of PARP in MDA-
M B-23 1 suggest that the reduced cell viabil ity observed in MDA-MB-231 
cel ls treated with low concentrations of Sal inomycin ($1 0jJM) resulted from 
a n  i nh i bit ion of cell prol iferation and was not caused by cel l  death . 
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Figure 1 3 . Stimu lation of Caspase 3/7 Activity in MDA-MB-231  Cells After 
Exposure to Sal inomycin ( 1 0  and 25 jJM)  for 24 and 48 Hours. 
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Figure. 1 4 . Western Blot Analysis Showing Dose-and Time-Dependent Induction of PARP Cleavage in Sal inomycin Treated MDA-MB-231 Cel ls . 
• represents non-specific band 
3.4 Sa l i nomyc i n  Induce s  Growth Arrest in M DA-M B-231 Cel ls  and 
I n h ib ited Colony Growt h  
T o  confirm that low concentrations of Sal inomycin induced growth 
inh ibition of M DA-MB-23 1 ,  cel ls  were treated with DMSO or Sal inomycin 
( 2 . 5  and 5 IJ M )  and kept in a culture for 6 days then cell viabi l ity was 
m easured after 1 ,  3 and 6 days by counting viable cel l s  using Trypan Blue 
Exclusion Assay. F igure 1 5  clearly shows that whi le DMSO treated MDA-
MB-231  cel l s  continued to prol iferate, Sal i nomycin-treated cel ls exhibited 
a strong inh ibit ion of prol iferation. Moreover, the inhib ition of cel lu lar 
prol iferation induced by low concentrations of Sal inomycin persisted even 
upon removal of the drug further indicating that, a low concentration of 
Sal inomycin induces a permanent cel l  cycle arrest of the MDA-MB-231  
cel ls .  These results along with the cell viabi l i ty data strongly suggest that 
Sal i nomycin has a d ifferential effect on the M DA-MB-231  cel ls depending 
on the concentration u sed . At low concentrations, Sal inomycin inh ibits 
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cel lu lar prol iferation without inducing cell death , whi le at h igh 
concentrations it exerts i ts effects by inducing apoptosis through activation 
of caspase 3/7 and PARP cleavage. 
To further confi rm the growth arrest potential of Sal i nomycin on 
M DA-MB-231  cel ls ,  we sought to determine if Sal inomycin inh ibits the 
growth of formed colonies. Figure 1 6  shows that the size of a control 
g roup of DMSO-treated colonies kept growing after three weeks 
compared to the size of the control colonies at two week; more large and 
medium size colonies are obtained in  the three week plate, whi le fewer 
smal l  colonies were counted , ind icating that medium colonies became 
larger i n  size and smal ler ones became medium sized colonies. 
I n terestingly ,  the colony sizes counted in  the three week Sal inomycin­
treated plates were ind ist inguishable from those in  the two week control 
DMSO-treated plates, ind icating that Sal i nomycin was able to completely 
block the growth of the M DA-MB-231  colonies. Th is data further confirm s 
the growth inh ib i tory effect of low concentrations of Sal inomycin on the 
prol iferation of M DA-MB-231  cel ls .  
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Figure 1 5. I nh ibition of Prol iferation by Sali nomycin in MDA-MB-23 1  
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Figure 1 6 . I nduction of Growth Arrest by Sal inomycin in MDA-MB-231  
Cel ls .  
3.5 S a l i nomycin Induced G2 Arrest and Senescence in M DA-M B-231 
Ce l ls  
To examine the mechanism for Sal inomycin- induced growth 
inh ibi tion ,  cel l  cycle d istribution was analyzed by flow cytometry. MDA-
M B-23 1  cel ls were treated with the ind icated concentrations of 
Sal inom ycin (5 ,  1 0  and 2 5  �M)  for 24 and 48 h .  
As shown i n  figure 1 7 , the concentration of Sal inomycin at 1 0  and 
25 �M cau sed an obvious G/2M arrest to the MDA-MB231 cel ls in  a 
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Figure 1 6 . I nduction of Growth Arrest by Sal inomycin in  M DA-MB-23 1 
Cel ls .  
3 .5  Sa l inomyc i n  Induced G2 Arrest and Senescence in  M DA-M B-231 
Ce l ls  
To examine the mechanism for Sali nomycin-induced growth 
inh ibition ,  cel l  cycle distribution was analyzed by flow cytometry . MDA-
M B-23 1  cel l s  were treated with the ind icated concentrations of 
Sal inomycin (5 ,  1 0  and 25 IJM)  for 24 and 48 h .  
As shown in  figure 1 7, the concentration of Sal inomycin at 1 0  and 
25 IJ M  cau sed an obvious G/2M arrest to the MDA-MB23 1 cel ls in a 
55 
concentration and time-dependent manner. The population of G2/M 
increased from 28% in DMSO-treated cel ls  to 33 and 44% at 24 hours , 
respectively (fig .  1 7 , upper panel) .  Simi larly, the G2/M population 
increased from 22 to 43.6 and 49.67% at 48 hours,  respectively (fig . 1 7 , 
lower panel ) .  Surprisingly, at lower concentration (2 .5 and 5 �M) ,  
Sa l inomycin was found to induce a transient cel l  cycle arrest in G 1  and 
G 2/M over time.  In fact, Sal inomycin induced an accumulation of cel ls in 
G 1 phase at 24 hours and successive accumulation in the G2 phase at 48 
hours post-treatment. 
To determine whether Sal inomycin induced cel l  cycle arrest 
specifica l l y  at m itosis or G2 phase, we examined the phosphorylation 
status of H istone H3 (Ser 1 0) .  H istone H3 is phosphorylated at serine 1 0  
during m itosis by aurora kinase and the phosphorylation status of H 3  is 
considered as a marker of mitosis [ 1 32]. We therefore, investigated the 
expression of p( ser1 0)H3 and found a time and dose-dependent decrease 
in the phosphorylation level of H istone H3 in response to the Sal inomycin 
treatment (fig .  1 8 , upper panel ) . This result indicated that Sal inomycin 
indu ced G2 arrest of MDA-MB231 cel ls .  We also examined the expression 
of cycl i n  B 1  in Sal inomycin treated cel l s. An accumulation of cycl in B 1  is 
wel l  known to play an important  role in G2/M transition. Knock-down of 
cycl i n  B 1  with si RNA produces cell cycle arrest predominantly i n  the G2 
phase [ 1 33],  whi le an upregulation of cycl in B1  invokes m itotic arrest 
[ 1 34] . We found that Sal inomycin a lso decreased cycl in B 1  level in a time­
and dose-dependent manner (fig .  1 8 . m iddle panel) ,  further confirming 
that Sal inomycin induced a cel l  cycle arrest in the G2 phase in  M DA-MB-
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2 3 1  cel ls .  However, a sensitive decrease of cycl in B 1  began at higher 
concentrations of Sal inomycin .  
G 1  arrest observed a t  2 4  hours with low concentrations of 
Sa l i nomycin prompted us to examine the expression leve ls  of cycl in 01  
protein involved in the control of  the G 1 /S transition.  I t  has  been shown 
that overexpression of cycl i n  0 1  shortens the G 1  phase and occurs in 
many types of human cancers, whereas inh ibition of cycl in 01 expression 
b locks G 1 -S transition [ 1 35- 1 37]. As shown in Figure.  1 8  ( lower panel ) ,  
the l evel of cycl in 0 1  decreased upon treatment with Sal inomycin in a 
time- and dose-dependent manner. Remarkably, no cycl in 0 1  protein was 
detected at 48 hours with a h igh concentration of Sal inomyci n .  
M OA-M B-23 1 cel ls  treated with low concentrations of Sal inomycin 
exh i bited the behavior of senescent cel ls characterized by cel l viabi l ity; 
m etabol ica l ly active and perm anently growth arrested . Therefore, we next 
d etermined whether the growth arrested MOA-MB-23 1 cel ls  did indeed 
undergo senescence. It is wel l  known that senescent cel ls  express a 
senescence-associated �-galactosidase (SA-�-Gal) ,  wh ich is detected by 
i ncubating cel ls  with X-gal at a p H  of 6.0 .  Our resu lts show that 30% of 
Sal inomycin-treated cel ls  expressed SA-�-galactosidase (fig . 1 9), 
i nd icating that i nduction of senescence contributes to the inh ibitory effect 
of Sal inomycin on the prol iferation of M OA-MB-231  cel ls .  
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Figure 1 7 . F low Cytometry Analysis of Salinomycin- induced G2 Cel l -Cycle 
Arrest in MDA-MB-231  Cel ls .  
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Figure 1 8. Western B lot Analysis of p(ser1 0) h istone H3 ,  cycl in B1 and 
cycl i nD1  Expression in Sal i nomycin Treated MDA-MB-23 1 .  
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Figure 1 9 . Sal inomycin I nduced Senescence in M DA-MB-231  Cel ls After 
I ncu bated with 5 IJ M  Sal inomycin for 96 Hours and Stained for SA-�­
Galactosidase Activity. 
3 .6  Sal inomycin  I n duced activation of yH2AX, a Marker of Double 
Stra nd Breaks, i n  M DA-M B  231 Cel ls  
Several  studies showed that cel ls  can undergo premature 
senescence in respon se to exposure to oxidative or genotoxic stresses 
that cause DNA damage. In terestingly, Sal inomycin was shown to induce 
an elevation in the intracel lu lar reactive oxygen species ( ROS) levels and 
m itochondrial membrane depolarization [ 1 1 8] .  Moreover, Sal i nomycin was 
a lso shown to induce DNA damage in MCF-7 and H s578T human breast 
cancer cel ls [1 2 1 , 1 22] .  Therefore, we sought to investigate whether 
Sal inomycin induced DNA damage in M DA-MB-231  cel ls as wel l .  For this 
purpose, MDA-MB-2 3 1  cel l s  were cultured for 6,  24 and 48 hours in 
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Figure 1 9. Sal i nomycin I nduced Senescence in  M DA-MB-231  Cel ls After 
I ncubated with 5 IJ M  Sal inomycin for 96 Hours and Stained for SA-�­
Galactosidase Activity. 
3.6 Sa l inomycin  I n duced activation of yH2AX, a Marker of Double 
Strand  Breaks, in M DA-M B  231 Cel ls  
Several stud ies showed that cel ls can undergo premature 
senescence in  response to exposure to oxidative or genotoxic stresses 
that cause DNA damage. In terestingly, Sal inomycin was shown to induce 
a n  e levation in  the intracel lu lar reactive oxygen species ( ROS) levels and 
mi tochondrial membrane depolarization [ 1 1 8] .  Moreover, Sal i nomycin was 
a lso shown to induce DNA damage in MCF-7 and Hs578T human breast 
cancer cel l s  [ 1 2 1 , 1 22] .  Therefore, we sought to investigate whether 
Sal inomycin i nduced DNA damage in MDA-MB-2 3 1  cel ls  as wel l .  For this 
purpose, MDA-MB-231  cel ls were cultured for 6, 24 and 48 hours in  
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com plete media conta in ing either DMSO or an Increasing concentration of 
Sal inomycin (5-50 I-IM) .  DNA damage was determined by measuring the 
levels of phosphorylated H2AX (yH2AX) in non-treated and Sal inomycin-
treated cel ls.  Western blot analysis revealed a concentration- and t ime-
dependent increase In  the levels of yH2AX (fig.  20) in  the MDA-MB-23 1  
cel ls  in  response to the Sal i nomycin treatment, indicating a n  accumu lation 
of double strand breaks in these cel ls .  An increase in  DNA damage was 
a lso assessed by Imm unofluorescence sta in ing of yH2AX in cel ls treated 
with 1 0  and 50l-lM Sal inomycin for 24 hours.  Figure 2 1  clearly shows a 
concentration-dependent Increase of yH2AX foci in  response to 
Sal inomycin .  S ince the activation of yH2AX occurs even at concentrations 
of Sal inomycin that do not lead to cel l  death (5 and 1 0I-lM), th is ru les out 
the possib i l ity that the resu lting DNA damage is a consequence of DNA 
fragmentation result ing from Caspase 3/7 activation and further confirming 
the potential of th is  drug to induce double strand DNA breaks i n  a 
concentration-dependent manner. 
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Figure 20.  Western B lot Analysis of Phosphor-H2AX (Ser 1 39) in M DA­
M B-23 1  Cells Treated for 6, 24 and 48 Hours with DMSO or I nd icated 
Concentrations of Sal inomycin .  
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Figure 2 1 .  I mmunofluorescence Stain ing for yH2AX in Sal inomycin 
Treated M DA-MB-231  cel ls .  
3.7 Sa l inomycin I n duced p53- lndependent Upregu lation of p21 waf/ciP 
i n  Growth Arrested M DA-M B-231 Ce l ls  
Becau se p2 1 protein has been reported to inh ibit growth and 
apoptosis and mediate senescence, we investigated whether the growth 
inh ibit ion and senescence mediated by Sal i nomycin was associated with 
an induction of p2 1 .  MDA-MB-23 1  cel l s  were cultured in the presence of 
DMSO or a n  increasing concentration of Sal inomycin for 6, 24 and 48 
hours. Western blot analysis of p21 level i n  Sal inomycin-treated cel l s  with 
concentrations causing growth arrest and senescence showed an 
increase in the protein level detected starting from 6 hours of treatment 
(fig .  22) .  At the concentrations of Sal inomycin causing cel l death , we 
observed that while a concentration of 50 IJM caused a quick decrease of 
6 1  
p2 1 level detected as early as 6 hours, a concentration of 25 �M,  
however, led to a transient increase of p2 1 at  6 hours fo l lowed by a 
decl ine in  the protein level at 24 and 48 hours (fig .  22) .  These 
observations were further confirmed by immunofluorescence stain ing of 
p2 1 in cel l s  treated with 1 0  � M  Sal inomycin (fig .  23).  As expected , no 
induction of mutant p53 in the M DA-M B-23 1 cells was observed , thus 
strongly suggesting that the induction of p2 1 by Sal inomycin in M DA-MB-
231  cel ls  occurred independently of p53 function.  
The levels of another CDK inh ibitor, p27 was a lso determ ined at 24 
and 48 hours post-treatment. As it  is  shown in  figure 24, the level of p27 
showed a concentration and time-dependent decrease in M DA-MB-23 1 
cel ls .  
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Figure 22 .  Western Blot Analysis of p2 1 Expression in Sal inomycin 
Treated MD-MB 2 3 1  Cells. 
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Figure 23 .  I mmunofluorescence Stain ing for p2 1 in Sal inomycin Treated 
M DA-M B-23 1 Cel ls. DAP I is used as a nuclear sta in .  
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Figure 24.  Western Blotti ng Analysis of p27 Expression in M DA-MB-231  
Cel l s  u pon Sal inomycin Treatment. 
3.8 Sa l i nomyc i n  I nduced Downregu lation of Survivi n Expression in 
M D A-M B-231 Ce l ls  
Survivi n ,  a member of  the inh ibitor of apoptosis protein ( lAP) fami ly, 
p lays an important role in  both the regu lation of cel l cycle and the 
inh ib it ion of a poptosis .  However, a decrease in survivin l evels has been 
shown to sensitize cel ls  to apoptosis. Therefore, we examined the 
possib le  i nvolvement of survivin in cell cycle arrest and apoptosis as 
triggered by Sal inomycin .  Toward this end, we analyzed , by Western 
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blotting ,  the expression of survivin In  response to vanous concentrations 
of Sal l nomycin after 24 and 48 hours of treatment. As shown In figure 25, 
whi le low concentrations of Sal i nomycin led to no obvious change in 
survivin expression , h igher concentrations (25 and 50 �M) ,  caused a 
drastic decrease In  survivin protein level at 24 and 48 hours, consequently 
sensitizing M D-MB-231  to cel l  death . The persistence of survivin 
expression at concentrations causing growth arrest and senescence cou ld 
a l so account for the resistance to cell death of Sal i nomycin-treated cel ls. 
Sahnomycln  Ill." 0 
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Figure 25 .  Western Blot Analysis of Survivin Expression in Sal i nomycin­
Treated M DA-MB 231  Cel l s. 
3.9 Sa l i nomycin  I nd uced Hyperacetylation of Histone H3 and H4 in  
the  M DA-M B-231 Ce l ls  
The expression of p21  and increased h istone hyperacetylation 
have been previously l inked to apoptosis, growth arrest and cel lu lar 
senescence. Therefore, we examined the acetylation profi le of H istone H3 
and H4 I n  M DA-MB-231  cel l s  at 6, 24 and 48 hours with increasing 
concentrations of Sal inomycin .  I n  figure 26, time course analysis showed 
a gradual  increase in acetylated Histones, H3 and H4.  A marked overal l  
i ncrease in  the acetylation status of h istone H3 and H4 was a lso detected 
by i m m unofluorescence sta in ing (fig .  27) .  Altogether, these results show 
that Sal inomycin induces acetylation of H istone H3 and H4 .  
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Figure 26. Western Blot Analysis of Ac-H3 and Ac-H4 Expression in  
Sal inomycin Treated M DA-M B 231  Cel ls. l3-act in was used as load ing 
control . 
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Figure 27 .  Immunofluorescence Staining of Ac-H3 and Ac-H4 in MDA­
M B-23 1  Cel ls  Treated with 1 0  and 25 IJM Sal inomycin for 24 hours.  DAPI 
was u sed as a nuclear sta in . 
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3. 1 0  Combi nation of Sa l inomyc in  with Frondoside A or with 4-
Hyd roxy-Tamoxifen  Enhanced Ce l l  Death and Act ivat ion of 
C aspase3/7 
Recently, frondoside A ( Fr), a triterpenoid g lycoside isolated from 
the sea cucum ber, Cucumaria frondosa, has been shown to Inh ibit 
surviva l ,  m igration ,  and i nvasion of MDA-M B-231  cel ls [ 1 38] . In vivo, 
frondoslde A strongly decreased the growth of MDA-MB-231 tumor 
xenografts In athymic m ice, without precipitating sign ificant toxic side-
effects. Although frondoside A is not used as an anti -cancer drug, we 
decided to Investigate whether Sal inomycin could sensitize MDA-MB-231  
cel ls  to th is  com pound . We have chosen to use 1 IJM of frondoside A, a 
concentration that induces 30% inh ibition of cel lu lar  viabi l i ty. Remarkably, 
frondoside A potentiated the growth inh ibitory effect of different 
concentrations of Sa l inomycin (fig .  28).  
We next exami ned the efficacy of Sal inomycin (2 .5-50 IJM) in 
combination with 4-Hydroxy-Tamoxifen (20 IJM) ,  the active metabol ite of 
tamoxifen , the breast cancer drug, in  MCF-7 cel ls .  Combined treatment 
caused a sign ifica ntly greater inh ib ition in  cel lu lar  viabi l ity than treatment 
with either drug a lone (fig .  29) after 48 hours of treatment. Moreover, a 
combination of Sal inomycin with 4-Hydroxy-Tamoxifen sign ificantly 
i ncreased the activation of Caspase 3/7, suggesting that apoptosis is 
h igher compared with treatment with either drug a lone (fig .  30). 
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Figure 28 .  Sal inomycin Enhanced Cel l  Death I nduced by Frondoside A in  
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Figure 29. Sa l inomycin Enhanced Cel l  Death I nduced by 4 Hydroxy­
Tamoxifen in MCF-7 Cel ls .  
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Figure 30 .  Sa l inomycin Induced Synergistic Apoptosis Against MCF-7 
Cel ls .  F r  represents frondoside A, Sal ino represents Sal inomycin and 4-
HT represents 4-Hydroxy-Tamoxifen . 
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DISC U SSION 
Common cancer treatment drugs aim at Inducing cel l death and 
apoptosis,  which are considered prerequisites for preventing mal ignant 
cell g rowth .  Several studies have demonstrated that cel lu lar senescence 
can occur in VIVO and may provide a critica l barrier for cancer 
development and cancer progression [1 39] . In fact, treatment of cancer 
cell l i nes with different chemotherapeutic drugs induces i rreversible 
growth arrest associated with senescence l i ke-phenotype [ 1 40 ,  1 41 ] . 
I ndeed , induced-senescence appears to be a promising a l ternative 
strategy for cancer treatment. 
Our  present work shows that ( 1 ) Sal inomycin significantly 
decreased viabi l i ty of the wi ld-type p53 MCF-7 and T470 as  wel l as 
m utant  p53 M OA-MB-231  human breast cancer cel l  l ines in  concentration 
and tim e-dependent manners, and that (2)  M OA-MB-231  cel l s  respond 
d ifferent ly to low and high concentrations of Sal inomycin .  Our results 
demonstrate that h igh concentrations of Sal inomycin (25 and 50 �M) 
induce G2 arrest, downregu lation of survivin and activation of the 
a poptotic s ignal ing pathway result ing in the activation of Caspase 3/7 and 
PARP cleavage .  This fi nding IS in agreement with previous reports 
demonstrating that the anti-cancer effect of Sal inomycin on d ifferent 
cancer cel l  l i nes was due to its apoptosis-inducing activity [ 1 1 5 , 1 1 8 ,  1 23, 
1 42] .  I n terestingly, our results show for the fi rst tim e  that low 
concentrations of Sa l lnomycln (:51 O�M) Induce senescence In M OA-MB-
2 3 1  cel ls.  We found that Sal inomycin -treated MOA-MB-231  cel ls  exhibited 
markers of senescence including SA-f3-galactosidase activity, changes in 
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m orphology, cel l cycle arrest, H istone H3 and H4 hyperacetylatlon and 
elevated expression of the cycl in-dependent kinase inh ibitor, p2 1 .  We also 
report that Sal inomycin enhanced the ki l l ing of the MCF-7 and MDA-MB-
2 3 1  cel ls by chemotherapeutic agents, 4-Hydroxy-Tamoxifen and 
frondoside A, respectively. 
We showed that data on the cel l  viabi l i ty of M DA-MB-23 1 
determi ned by Cel lTiter-Glo and Trypan Blue Exclusion were not super­
i mposab le  even though they fol low the same pattern i .e .  growth inh ibition 
at lower concentrations and cell death at h igher concentrations.  CellTiter­
G lo  Assay which is based on quantification of the ATP present showed 
less effect on the viabi l i ty of the M DA-MB-231 compared to the Trypan 
B lue  Exclusion Assay when the same concentration was used . 
I nterestingly ,  it has been reported that DNA-damaging agents such as 
etoposide and temozolomide induce an ATP surge in  cancer cel ls [ 1 43], 
which expla ins the d ifferences observed between Cel lTiter-Glo and 
Trypan Blue Exclusion Assay in Sal inomycin-treated M DA-MBA-231  cel ls. 
In our study, we observed that at a concentration of 2.5 and 5 jJM, 
Sa l inomycin induced a G1 arrest at 24 hours and G2 arrest at 48 hours 
post-treatment. Earl ier reports have shown that low concentrations of 2 .5  
and 5 jJM of  Sal i nomycin a lso induced a G 1  arrest in the MCF-7 and 
Hs578T breast cancer cel ls after 24 hours of treatment [ 1 22,  1 23] which is 
i n  agreement with our data on the M DA-MB-23 1 cel ls .  However, no further 
concentrations or t ime points were tested. Cycl in 0 1 , a cycl i n  requi red for 
G 1  to S transition, was found to be reduced upon Sal inomycin treatment 
and  cou ld  be the main cause for the G 1 block. Our data a lso suggested 
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that cel l  cycle arrest at the G2 phase might be med iated by the reduction 
of cycl l n  B 1 .  Moreover, the level of cyclin B 1 at 5 IJM Sal inomycin seemed 
to decrease at later times than cycl in 0 1  decreased . I nterestingly, 
Curcumin  was a lso shown to induce a successive G 1 /S arrest at earlier 
t imes and G2/M phase arrest at later time point in HOS cel ls  [ 1 44]. The 
exact mechanism by which cel l s  undergo a transient G 1  arrest fol lowed by 
a G2 arrest remains unclear. Our data also showed , for the first time, that 
Sal inomycin at higher concentration induced a robust G2 arrest confirmed 
by cycl in B 1  decrease and p(ser1 0) H istone H3.  The cel l  cycle arrest data 
i s  in agreement with the growth inh ibition data shown by cell viabi l ity (fig 1 ,  
5 ,6 ,  1 5) and colony growth assay (fig .  1 6 ) .  Interestingly, we found that the 
COK inh ib itor p27, a lso a marker of G 1  arrest, was downregulated during 
the transient G 1  arrest observed at 5 IJ M .  This is not surprising as a report 
by Yongxlan and Miskimins showed that G 1  arrest in M OA-MB-231 breast 
cancer cel ls  treated with m etformin  involves down reg ulation of cycl in 0 1  
a n d  requ i res p27 o r  p2 1 [ 1 45] .  
I n h ibitor of Apoptosis Proteins ( lAPs), which incl udes survivin ,  
represents a fami ly of anti-apoptotic proteins that bind and i nactivate 
Caspase 3, 7 and 9 [ 1 46- 1 48] and can modulate cell d ivision and cel l 
cycle progression [ 1 49] . Survlvin has been shown to be h igh ly expressed 
in most cancers, where it  functions as an inh ibitor of apoptosis .  In breast 
cancer, overexpressed survivin was shown to protect cel ls against 
a poptosis induced by chemotherapeutic agents, such as Etoposide [ 1 50] . 
I n  con sideration of the role  of survivin as a custodian of cancer cel l  
surviva l ,  our  results suggest that Sal inomycin at h igh  concentration might 
7 1  
exert Its CytOtOXIC anti -cancer effects at least partly via the down­
reg ulation of SUrvIVIn .  
Senescent cel ls are known to remain viable and metabolica l ly 
active, but are permanently growth arrested [ 1 5 1 ] .  Growth arrest is 
ach ieved and mainta ined In  either G1 or G2/M stage of cel l  cycle ,  at least 
th rough overexpression of specific cycl in-dependent kinase inh ibitors such 
as p 1 6, p2 1 and p27 [ 1 39] [1 52-1 54] . Schwarze et al have previously 
shown that p2 1 is more important i n  cel l  cycle arrest that is associated 
with early senescence, whi le p 1 6  a ppears to be important for maintain ing 
the senescence phenotype [ 1 52] .  Senescence is  triggered by DNA 
damage to cel ls  which respond via the induction of a group of genes 
responsib le for the development of the senescence phenotype [ 1 55] . The 
decision of the cell to undergo either apoptosis or senescence is 
dependent, at least i n  part. u pon the magn itude of DNA damage caused 
to cancer cel ls. Low levels  of DNA damage may induce senescence 
without activating the apoptotic pathway. Several studies reported that 
many senescence inducing drugs generate DNA damage. In  fact, 
treatment of prostate cancer cel ls  with h igh doses of doxorubicin ,  a DNA­
damage ind ucing chemotherapeutic drug,  leads to apoptosis, while a 
lower dose of doxorubicin induces senescence [1 56]. Furthermore. 
doxoru bicin was shown to induce senescence in numerous cancer cell 
l ines, including those lacking p53 [ 1 57] .The same observation was made 
when cisplat in [ 1 58]. hydroxyurea [ 1 59] or bromodeoxy urid ine [ 1 60] were 
used . 
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The expression of the cycl i n-dependent kinase inhib itor p2 1 has 
been imp l icated In  chemotherapy induced cell cycle arrest in various 
human cancers [ 1 52 , 1 53,  1 6 1 - 1 63].  The contribution of p2 1 to cel lular 
senescence has been demonstrated by numerous studies [ 1 52-1 54] . I n  
fact, p2 1 h a s  been found to b e  upregulated i n  senescent cel ls .  Moreover, 
forced overexpression of p21  was shown to be sufficient to induce cel l  
cycle arrest, and premature senescence in wild -type and mutant p53 cel ls 
[ 1 55] .  I n  l ine with th is  data , we reported that Sali nomycin at concentrations 
of $; 1 0  IJM IS able to Induce mainta ined upregu latlon of p21  expression In 
the M DA-MB-231  cel ls .  Based on these data , we propose that induction of 
senescence in Sal inomycin-treated MDA-MB-231 breast cancer cel ls  is 
m ediated , at least, partly through a p53-independent upregulation of p2 1 
protein and does not involve p27 since, its expression decreased in a 
tim e- and dose dependent manner (fig .  24) .  
I t  has a lso been reported that cel lu lar  senescence is associated 
with mod ifications in  chromatin structure [ 1 56, 1 57].  H istone 
hyperacetylation has been d irectly l i nked to the upregulation of p2 1 and 
th is  activation can a lso occur independently of p53 [39] . Our data showed 
that Sal inomycin induced Histone H3 and H4 hyperacetylation . We have 
a l so found that h istone hyperacetylation correlated with a p53-
independent upregu lation of p2 1 expression and growth inh ibition in  the 
M DA-M B-231  cel ls .  Our data suggest that H istone H3 and H4 
hyperacetylation cou ld be one of the mechanisms through which 
Sal i nomycin exerts its anti-cancer activity, at least, in breast cancer. 
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Recent studies reported that Sal inomycin potentiates the antI­
cancer activity of several DNA damage-inducing chemotherapeutic drugs 
[ 1 2 1 ]  as wel l  as sensitizes cancer cel ls to radiation [ 1 22] .  Sal inomycln 
was a lso shown to sensitize cancer cel ls  to inh ibitors of DNA replication 
[ 1 20] and to antimitotic drugs [ 1 23] . Consistent with these reports, our 
resu lts show that Sal inomycin indeed potentiates the anti -cancer activity 
of two other drugs,  namely frondoside A and the anti-estrogen 4-Hydroxy­
Tamoxifen in MDA-MB-2 3 1  and MCF-7 respectively. 
In summary,  our study is  consistent with the model shown in figure 
3 1 , i n  which treatment with Sa l inomycin induces double strand breaks, 
revea led by an accumulation of yH2AX. The magnitude of DNA damage. 
which depends on the concentration of Sal inomycin ,  determines the 
response of the cel ls to th is  damage. We propose that the presence of 
large amounts of DNA damage induced by high concentrations of 
Sal inomycin .  M DA-MB-2 3 1  cel ls respond by triggering the apoptotic 
s ignal ing pathway through activation of Caspase 3/7 and cleavage of 
PARP. I n  contrast, l im ited DNA damage caused by low concentrations of 
Sal inomycin triggers a rapid program of senescence which is mediated , at 
least partly, through hyperacetylation of H istone H3 and H4 which 
subsequently results in the u pregu lation of p21 expression.  
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Figure 3 1 . Hypothetic Model for the Differentia l  Effect of Sal inomycin in 
M DA-MB-231  Breast Cancer Cel ls. 
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CHAPTER 3 :  R E S U LTS AND DISCUSSION 
Part I I .  Ant i-Tumor Growth a n d  Ant i -Metastat ic Activity of Origanum 
majorana Extract on the Tri ple Negat ive Breast Cancer 
3 . 1 2  O. majorana Extract I nh i bited the V iab i l ity of the MDA-M B-231 
Breast Cancer Ce l ls  
To examine the anticancer activity of  Origanum majorana extract 
(OM E) on breast cancer cel ls ,  we first measured the effect of various 
concentrations of the extract (0 ,  50, 1 50 ,  300, 450 and 600 �g/mL) on the 
prol iferation of the MDA-MB-231  breast cancer cell l ine (fig .  32). Our 
resu lts show that exposure of the MDA-M B-231  to OME decreased 
cel lu lar viabi l ity in a concentration- and a time-dependent manner. The 
I Cso (producing half-maximal inh ibition ) was approximately 350 �g/mL at 
24 hours and 400 �g/mL at 48 hours treatment.  Observation of the OME-
treated MDA-MB23 1 cel l s  under l ight microscopy a lso revealed that the 
number of cel l s  decreased when the concentration increased . 
Furthermore, as shown in figure 33, l ight m icroscopy observation of MDA-
M B23 1 cel l s  treated with concentrations of 1 50 ,  300 and 450 and 600 
�g/mL OME,  underwent morphologica l  changes characterized by a loss of 
their epithel ia l  morphology visible after 24 hours of treatment. Echinoid 
spikes and cel lu lar rounding,  characteristics of apoptotic cel ls were a lso 
observed. 
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Figure 33 . M icrograph of MDA-MB-231 Cel ls After 24 Hours I ncubation 
with Variou s  Concentrations of OME.  
77 
3 . 1 3  O. majorana Extract Lead to M itot ic Arrest and Apoptos is in  
M DA-M B-231 Ce l ls  
The abi l ity of an anticancer drug to affect cel l  cycle distribution can 
provide information regarding its cytotoxic mechanism(s) of action . For 
th is  reason ,  we investigated the effect of OME on cel l cycle d istribution 
u sing flow cytometry. MDA-MB 231  cel ls  were treated with the indicated 
concentration of O. majorana for 24 hours and subjected to cel l cycle 
analysis. At a concentration of 1 50 f.jg/mL ,  OME caused an obvious G/2M 
arrest of these cel ls  (fig .  34) .  I ndeed , the population of G2/M increased 
sign ificantly from 23 to 5 1 .7% as the concentration of the OME increased 
to 1 50 f.jg/mL ,  indicating that O M E-treated MDA-MB-23 1  cel ls  were 
arrested in the G2/M phase. A sl ight increase in the sub-G 1 population 
(6 .2%)  was a lso observed by these concentrations indicating that a smal l  
popu lation of OM E-treated M DA-MB-231  cel ls is undergoing cel l  death . 
I n terestingly,  at h igher concentrations of OME,  flow cytometry analysis 
revealed a dramatic increase in the apoptotic population (sub-G 1 peak) 
rising from 0 .9% in the control group to 48.4% and 56.7% in cel ls  treated 
with 600 and 450 f.jg/mL ,  respectively (fg .  34) .  
To determine whether OME specifica l ly induced cel l cycle arrest at 
m itosis or the G2 phase, we examined the phosphorylation status of 
H istone H 3  ( Ser 1 0) .  H istone H3 i s  phosphorylated at serine 1 0  during 
m itosis by aurora kinase and the phosphorylation status of H3 is 
considered a marker of mitosis [ 1 32]. We therefore, investigated the 
expression of p( ser1 O)H3 and found that treatments 1 50 and 300 f.jg/mL 
of O. majorana significantly increased the phosphorylation level of Histone 
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H3 (fig .  35,  u pper pane l ) .  This result i nd icates that OME induces m itotic 
arrest of M DA-MB231 cel ls .  Next, we investigated the mechanism of 
OM E-induced m itotic arrest. Accumu lation of cycl in B 1  is well known to 
play an important  role i n  G2/M transit ion. Knock-down of cycl in B 1  with 
s iRNA produces cell cycle arrest predominantly in the G2 phase [ 1 33] , 
whi le an upregu lation of cycl in B 1 invokes mitotic arrest [ 1 34].  We, 
therefore, investigated the protein level of cycl in B 1 in OME-treated M DA­
MB-231 cel ls .  We found that treatment with these concentrations of OME 
leading to mi totic arrest, caused a lso an increase of cycl in B1  protein in 
M DA-MB-23 1  cel ls (fig .  35, lower panel) ,  suggesting that cycl in B 1  
accumU lation might play a crucial role i n  O M  triggered mitotic arrest . 
Taken together, our findings reveal a differential concentration effect of 
OME on cel l  cycle progression of MDA-M B  231  cel ls .  Whereas,  lower 
concentration s  of OME ( 1 50 and 300 IJg/mL)  i nduced a major m itotic 
arrest with a sl ight increase in the apoptotic population, h igher 
concentrat ions (450 and 600 IJg/mL)  induced massive cel l  death by 
a poptosis .  The reduced cel l  viabi l i ty observed in M DA-MB231 cel ls  treated 
with low concentrations of OME,  is possibly due to a large extent to an 
inh ibition of  cell prol iferation rather than to cel l  death . 
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Figure 34. Flow Cytometry Analysis Showing a G2/M Cell Cycle Arrest 
Induced by O. majorana Extract in M DA-MB-231  Cel ls.  
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Figure 3 5  . 75Western Blot Analysis of Phosphor(ser1 0)-H3 ,  and Cycl in 
B1 i n  O M E  Treated MDA-MB231 Cel ls .  
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Apoptosis in  OM E-treated M DA-M B-23 1 cel ls was further examined 
by m easuring Caspase 3/7 activation in  MDA-MB 231  cel ls treated with 
various concentrations (300,  450 and 600 IJg/mL)  of OME after 24 hours 
of treatment.  A concentration- and t ime-dependent activation of caspase 
3/7 was detected in treated cel ls  (fig 36) .  Interestingly, cleavage of the 
poly(ADP-ribose) polymerase (PARP) occurred only in cel ls treated with 
h igh er (450 and 600 IJg/mL) ,  but not at lower concentrations ( 1 50 and 300 
IJg/m l )  of OME (fig .  37) .  It is worth mention ing that at these lower 
concentrations of OME,  only a low a poptotic induction rate was observed 
despite the detection of Caspase 3/7 activation.  
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Figure 36.  Stimulation of Caspase 3/7 Activity in OME Treated in MDA­
M B-23 1  Cel ls. 
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Figure 37. Concentration-Dependent I nduction of PARP Cleavage in OME 
Treated M DA-MB231 Cel ls .  
3. 1 4  Concentration-Depe ndent Regulation of S u rv iv in  Expression by 
O. majorana Extract 
Survivin ,  a member of the inh ibitor of apoptosis protein ( lAP) fami ly,  
p lays an important role  i n  both the regu lation of cel l  cycle and the 
inh ibition of apoptosis. Survivin levels increase in the G2/M phase 
conferring resistance to a poptosis to the G2/M arrested cel ls .  However, a 
d ecrease in survivin levels sensitizes the cel ls to a poptosis. Several 
studies have reported that survivin exerts its negative effect on apoptosis 
by inh ibit ing the activity of Caspase 3 ,  7 and 9. Therefore, we examined 
the possible involvement of survivin in cel l cycle arrest and apoptosis 
triggered by OME.  We ana lyzed, by Western blotti ng ,  the expression of 
survivin i n  response to various concentrations of OME after 24 hours of 
treatment. I nterestingly, we observed a differential concentration-effect of 
O M E  on survivin expression in  the MDA-MB-231 cel ls (fig .  38) .  We found 
that low concentrations of O M E  led to a substa ntial increase in the level of 
survivin ,  whi le h igher concentrations caused a drastic decrease of survivin 
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(99%). Based on these results, we concluded that OME exerts a 
concentration-dependent effect on MDA-MB-231  cel ls. Low 
concentrations of OME induced a mitotica l ly arrested cel ls accompanied 
by surv ivin  upregu lation which, in turn , conferred resistance to cel l  death 
to this population of cel l s, probably by inhibiting the activity of Caspase 3/7 
which was monitored by the absence of PARP cleavage at these 
concentrations. Treatment of MDA-MB-23 1  cel l s  with higher 
concentrations of O M E  caused a dramatic decrease in survivin expression 
and consequently sensitized MD-MB-231  cel ls  to apoptosis. 
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Figure 38.  Western Blot Analysis Showing A differential Effect on Survivin 
Expression by Different Concentrations of OME in  M DA-MB-231 Cel ls .  
3 . 1 5 O. majorana E xtract Activates the Extri nsic Pathway for 
Apoptosis v ia a n  U pregu lat ion of TNF-a and Activat ion of Caspase 8 
Having shown that OME induces the activation of the effector 
Caspases 3/7 , we looked at the activity of the in i tiator caspases of the 
extrinsic and intrinsic cel l  death pathway, namely Caspase 8 and Caspase 
9,  respectively. Surprisingly, no Caspase 9 activation was detected in 
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response to various concentrations of OME after 24 hours of treatment (fig 
39) .  On the other hand , caspase 8 activity i ncreased in a concentration­
dependent manner in  response to OME treatment (fig 39). This result 
demonstrates that the apoptotic effect of the extract on MDA-MB-231  i s  
dependent o n  caspase 8 activity, which impl icates only the extrinsic cel l  
death pathway since no caspase 9 activation was observed . After showing 
that the extrinsic  cel l  death pathway is impl icated in  OME-dependent 
a poptosis, we were then interested in  determ in ing how th is  pathway is  
activated by  OME.  We determ ined the changes i n  the expression level of 
the Tumor Necrosis Factor Alpha (TN F-a) In response to OME after 24 
hours of treatment. Western blot analysis revealed a clear increase in the 
level of TNFa In M DA-M B-231  cel ls in response to OME treatment (fig .  
40) .  The upregu lation of TN F-a was further confirmed by 
i mmunofluorescence assay (fig 41 ) .  Even though we have shown that 
O M E  exerts its effect via the activation of the extrinsic pathway of cell 
death , we cannot ru le out, at th is stage, the possib i l i ty of OM E-dependent 
a poptosis could a lso be triggered by another mechanism . 
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Figure 39.  o. majorana Induced Apoptosis by Activation of Caspase 8 
and but not Caspase 9 in M DA-MB-231  Cel ls .  
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Figure 40. Western B lot Analysis Showing An increase in Cel lu lar TNF-a 
Protein in  the M DA-MB-231  Cel ls Treated with OME.  
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Figure 4 1 . I m m unofluorescence Stain ing for TNF-a in OME Treated 
M DA-MB- 2 3 1  Cel ls .  
3. 1 6  O. majorana Lead to Depletion of Mutant p53 in MDA-MB-231  
and Upregulation of p21 wAF11CIP1 
N ext, we tested the effect of O M E  on the expression of the tumor 
suppressor p53 in MDA-MB-231 . Toward this aim , cel ls were treated with 
various concentrations of OME and the protein level of the mutant p53 
was determined.  We found that low concentrations of 1 50 and 300 IJg/mL 
of OME led to a sl ight increase in  the protei n  level of mutant p53 (fig .  42,  
upper panel) .  Most importantly, Western blotti ng analysis revealed 
apoptotic concentrations (450 and 600 IJg/m L of OME) lead to a lmost 
com plete depletion of mutant p53 in M DA-MB-231  cel ls .  This result is a 
potentia l ly  i mportant finding because of the role of mutant p53 protein  in 
human cancers. Because mutant p53 renders cancer cel ls more resistant 
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to a nti -cancer drugs, abol ishing mutant p53 may therefore offer a 
promising a pproach for cancer prevention and therapy. 
Because p21 protein has been reported to inh ibit growth and 
a poptosis, we investigated whether the growth inhibition mediated by low 
concentrations ( 1 50 and 300 IJg/mL of OME) was also associated with an 
induction of p2 1 .  Western blotti ng showed an upregulation of p2 1 protein 
with at least 2 .5  fold increases in cel ls  treated with low concentrations of 
O M E ,  wh i le  l i tt le or no effect on p2 1 expression was observed with higher 
concentrations of OME (fig .  42 ,  lower panel ). Based on that, we can 
postu late that p21 upregulation contributes, at least partia l ly ,  to the cell 
cycle arrest observed with lower concentrations, whi le it has l ittle or no 
role  in cel l  death occurring at h igher concentrations of OME.  
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Figure 42 . Western Blot Analysis Showing Expression Leve ls  of Mutant 
p53 and p2 1 in 0. majorana Treated M OA-MB-231 Cells. 
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3 . 1 7 O. majorana Extract Ind uced Hyperacetylation of H istone H3 and 
H4 in the MDA-M B  231 Cel ls  
Previously, expression of p2 1 and increased histone 
hyperacetylation has been l inked to apoptosis and to growth arrest. 
Therefore, we examined the acetylation profi le of h istone H 3  and H4 in  
M DA-M B-23 1  in  response to treatment for 24 hours to increasing 
concentrations of OME.  As shown in  figure 43, the t ime course analysis 
showed a gradual increase in  acetylated h istones, H3 and H4. A marked 
overal l  increase in the acetylation status of H istone H3 and H4 was a lso 
d etected by immunofluorescence stain ing (fig 44) .  Altogether, these 
resu lts showed that OME induced hyperacetylation of Histone H3 and H4. 
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Figure 43 .  Western Blot Analysis Showing Protein Levels of Ac-H3 �nd 
Ac-H4 ,  Extracted from O M E  Treated Cel ls .  �-actin was used as loading 
contro l .  
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Figure 44. Immunofluorescence Stain ing of Ac-H3 and Ac-H4 in  MDA­
M B23 1 Cel ls Treated with O M E  for 24 Hours. DAPI was used as a nuclear 
sta in .  
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3 .1 8 O. majorana Induced Activation of yH2AX, a Marker of Double 
Strand Breaks, i n  M DA-M B-231 Cel ls  
We sought to investigate whether OME induced DNA damage in 
M DA-M B-231 cel ls .  For th is  purpose, MDA-MB 231 cel ls  were cultured for 
6 and 24 hours in a complete media contain ing either ethanol (control )  or 
increasing concentrations of OME (75, 1 50 ,  300, 450 and 600 IJg/mL).  
DNA damage was determined by measuring the levels of phosphorylated 
H 2AX (yH2AX) after 6 and 24 hours of treatment of the MDA-MB-231 cel ls 
with OME.  Western b lot analysis revealed a t ime-and a concentration-
dependent increase in the levels of yH2AX in response to OME treatment 
(fig 45), i nd icating an accumulation of double strand breaks in these cel ls .  
The increase in DNA damage was a lso assessed by immunofluorescence 
sta in ing of yH2AX in cel ls treated with 1 50 ,  300 and 450 f.Jg/m L OME for 
24 hours. Figure 47 clearly shows a concentration-dependent increase of 
yH2AX foci In  response to OME.  Since the activation of yH2AX occurred 
as  early as 6 hours, a t ime in which no cel l  death or Caspase 3/7 
activation was observed (fig .  46), th is ru les out the possibi l ity that the 
result ing D NA damage is a consequence of DNA fragmentation resulting 
from caspases' activities and further confirms the potentia l  of th is OME 
extract to induce double strand DNA breaks in a concentration-dependent 
manner. 
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Figure 45 .  Western Blot Analysis of Phosphor-H2AX (Ser 1 39) in MDA­
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Figure 46. Immunofluorescence Staining for yH2AX in OME Treated 
M DA-MB 2 3 1  Cel ls .  
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Figure 47.  Caspase 3/7 Activation in O M E  Treated MDA-MB-231 Cel ls 
After 6 Hours .  
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3. 1 9  O. majorana Inh ib ited Colony Growth of MDA-MB-231 
To further confirm the inh ibitory potential of O. majorana on MDA­
M B  2 3 1  cel l s, we sought to determine if OME cou ld inh ibit the further 
growth of a l ready formed MDA-MB-231  colonies. For th is  purpose , MDA­
MB-23 1 cel ls  were first a l lowed to grow and form visible colonies in the 
absence of treatment. After 1 4  days of growth , colonies were incubated 
with ethanol  as a contro l ,  and with OME,  and al lowed to grow for one 
more week .  F igure 48 shows that the size of the ethanol-treated (control )  
colonies kept growing compared to the size of the two week colon ies;  
more large colonies were obtained in the three week plate, wh i le fewer 
sma l l  colonies were counted , ind icating that smal l  colonies became larger 
in size . I n terestingly,  OM treated colonies showed regression in colony 
size compared to the two week colonies. In OM-treated plates, the 
number of large size colonies counted was fewer than that obtained in the 
two week plate, whi le the number of smal l  colonies was significantly 
greater, suggesting size regression in the large colony induced by OME.  
Th is  resu lt  a long with the viabi l i ty and flow cytometry data confirm the anti­
cancer effect of OME on trip le negative mutant p53 MDA-MB-23 1 breast 
cancer cel ls .  
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Figure 4 8 .  I nh ibition of Colony Growth b y  O. majorana Extract. 
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3.20 O. majorana Attenuated the Migration Abi l ity of the MDA-MB-231 
Breast Cancer Cel ls  
As cell migration p lays a crucial role in tumor metastasis, we 
sought to investigate whether OME affects the migration behavior of MDA­
M B-23 1  cel ls.  We first measured the migration abi l ity of these cel ls by 
us ing a wound-heal ing migration assay. For this purpose, we performed 
the test with concentrations of OME and periods of treatment that were 
previously shown to be non-cytotoxic to the MDA-MB-231 . As shown in  
figu re 49, OME treatment significantly inh ibited wound healing cel lu lar 
m igration of MDA-MB-23 1 cel ls  i n  a concentration-dependent manner. 
The ab i l ity of OME to inhib i t  the m igration of MDA-MB-231 cel ls  was also 
m easured by using the Boyden Chamber Transwel l  Assay. For th is 
purpose, M DA-MB-231  cel l s  were seeded in  the upper wel l s  with or 
without 300 jJg/mL OME.  As shown in  Figure 51  and 52,  the number of 
O M E-treated cel ls  that migrated to the lower chamber, after 6 hours of 
treatment, was sign ifica nt ly reduced approximately th ree fold compared to 
the number of control cel l s. Cel l  viabi l ity of the OME-treated cel ls at the 
concentrations and time tested was not affected (fig. 50) thus confi rm ing 
that the inh ibitory effect on the M DA-MB-231 cel ls  moti l i ty was not due to 
the cytotoxic effect of OME.  Taken together this confirms the inh ibitory 
effect of O M E  on the migration potentia l  of MDA-MB-231  cel ls .  
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Figure 50.  Cel l  Viabi l ity After Incubation of MDA-MB-231  Cel ls with OME 
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Figure 5 1 . Boyden Chamber Transwel l  Assay I ndicating that OME 
inh ibited the Migration of M DA-MB-23 1  Cel ls .  
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Figure 52. Quantification of Migrated M DA-MB-231 Cel ls. 
3 .21  O. majorana P romoted Cel l-Cel l  Aggregation and Induced E­
Cadher i n U preg u lat ion in MDA-M B-231 Ce l ls  
Lost capacity for homotypic adherence is  a lso associated with 
cancer cel l m etastasis. To determine whether OME would affect the cel l -
cell adherence behavior of MDA-MB 23 1 ,  cel l  aggregation assay was 
conducted on a control and OME-treated cel ls.  We found that O M E  
significantly i ncreased the abi l ity of M DA-MB-231  cel ls to form cel l  
aggregates visib le  and as early as 30 minutes post-treatment (fig .  53). I t  is 
known that loss of E-cadherin expression promotes tumor progression 
and metastasis wh i le its overexpression prevents the invasion of tumor 
cel ls .  We therefore sought to examine the expression of E-cadherin in 
M DA-MB-231  cel l s  in response to OME exposure.  We first examined the 
protein level of E-cadherin  in MDA-MB-231  cel ls  treated with and without 
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OME.  As shown in figure 54, OME induced a significant increase of E-
cadherin protein i n  a concentration-dependent manner. This increase in E-
cadherin expression was further confirmed by immunofluorescence 
stain ing ( fig .  55) .  The expression of E-cadherin was mostly detected at 
cel ls junctions.  
Next we determined whether the effect of OME on E-cadherin 
expression was m ed iated through transcriptional regulation. Toward th is ,  
transcription activity was measured in cel ls  transfected with a Luciferase 
Reporter gene contain ing E-cadherin promoter and treated with and 
without O M E .  As shown in figure 56,  OM E induced a concentration-
dependent increase in the luciferase activity, thus indicating that OME 
positively regu lates the expression of E-cadherin a t  the transcriptional 
level . Taken together, the data clearly show that E-cadherin is upregulated 
by O M E  and further suggests that the expression of this protein could 
account for the inh ibition of cel lu lar migration and invasion.  
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Figure 53.  P hotograph Under Phase-Contrast Microscope (x1 00 
Magn ification) Showing Aggregated Cells After OME Treatment 
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Figure 54 . Western Blot Analysis of E-cadherin Expression in OME 
Treated M D-MB-231  Cel is.  
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Figure 55. Immunofluorescence Stain ing for E .cadherin in OME Treated 
M DA-M B  2 3 1  Cel is .  DAP I was used as a nuclear sta in .  
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Figure 56. E. cadherin Promoter Activity Fol lowing Transfection with A 
Luciferase Reporter Gene Contain ing E-cadherin Promoter i n  M DA-MB-
2 3 1  Cel ls .  
3.22 O. majorana Inh ib ited Invasive Capacity of MDA-M B-231 Cel ls 
Next, we examined the invasive potential of MDA-MB-23 1 cel ls in 
the Matrigel-coated Boyden Chamber in the absence , or presence, of 1 50 
�g/mL O M E .  The number of O M E-treated cel ls that has passed through 
the Matrigel coated membrane was markedly reduced by 55% (fig .  57,  
and 58) ,  indicating that OME can inh ibit the invasive abi l i ty of the MDA-
M B-23 1  cel ls .  
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Figure 57 .  O. majorana I n h ibited the Invasive Activity of M DA-MB-231 
Cel ls .  
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Figure 58 .  Quantification of I nvaded M DA-MB-231  into the Matrigel . 
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3.23 O. majorana Suppressed the Expression and the Activity of 
M M P-2 and MM P-9 and downreg u lated u PAR i n  M DA-M B-231 Ce l ls  
Matrix metal loproteinases (MMP) -2  and -9 ,  among other MMPs, 
are known to play an important role in breast cancer cel l invasion and 
metastasis. To test whether O. majorana inh ibits breast cancer cel l  
i nvasion by affecting the expression of MMP-2 and MMP-9, we decided to 
examine the expression levels  of MMP-2 and MMP-9 proteins in a 
conditioned medium using OME-treated MDA-MB-23 1 cel ls .  The protein 
level of MMP-2 and M M P-9 (fig .  59) were found to be sign ificantly reduced 
in response to OME treatment. RT-PCR analysis a lso revealed that the 
M M P-2 and M M P-9 m RNA level was reduced in M DA-M B-231 cel ls upon 
treatment with O M E  (fig .  60) indicating that OME can inhibit the 
transcription of MMP-2 and M M P-9 genes in these cel l s. 
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Figure 59. Effects of OME on the Secretions of MMP-2 and MMP-
9 in the Collected Conditioned Medium of OME Treated MDA-MB-
23 1 Cel ls.  
1 03 
RT-PCR 
OME (J,lg(mL) : 
o o ('f') 
- .. � MMP·9 
GAPOH 
MMP-2 
___ GAPOH 
Figure 60.  RT-PCR Analysis of the m RNA Levels of MMP-2 and MMP-9 
in M DA-MB-231  Cel ls Treated with OME for 24 Hours.  GAPDH was used 
as an i nterna l  contro l .  
Then , we decided to examine the effect of  OME on the activity of 
MMP-2 and M M P-9. M DA-M B-23 1 cel ls were treated with 1 50 and 300 
I-Jg/mL OME for 24 hours in serum free DMEM,  the media was col lected , 
concentrated and tested for MMP2 and MM P-9 activity by using gelati n 
zymography. As shown i n  figure 6 1 , MMP-2 and MMP-9 activities were 
sign ificantly reduced in response to OME treatment. Altogether, our 
results showed that OME sign ificantly inh ibi ts both , the expression and the 
activities of M M P-2 a nd M MP-9. 
The Urokinase Plasminogen Activator ( uPA) and its receptor 
(uPAR) were a lso shown to play a crucial role  in breast cancer cel l  
invasion and metastasis. Therefore, we examined whether OME also 
a l ters the expression of u PAR. Western blot analysis clearly shows that 
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the expression level of u PAR decreased markedly in  OM E-treated MDA-
MB-23 1 cel l s  ( fig .  62) .  
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Figure 6 1 . Activit ies of MMP-2 and MMP-9 in  OME Treated MDA-MB 
23 1 Cel ls .  
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Figure 62.  Western Blot Analysis of uPAR Expression in  OME Treated 
M D-MB-23 1  Cel ls. �-actin is used as load ing control . 
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3.24 O. majorana Decreased Ad hesion of MBA-MB-231 to HUVEC and 
downreg u lated the Expression of ICAM-1 in Breast Cancer Cel ls 
The attachment of tumor cel ls  to endothel ia l  blood vessels is a lso a 
crucia l  event in  the process of metastasis. The effect of OME on MDA­
MB-231  cell adhesion to TNF-a stimu lated HUVECs was then investigated 
by co- incu bating both cel l types for 1 hour with,  and without various 
concentrations of OME. Figure 24A shows that OME sign ificantly inh ibited 
the adhesion of MDA-MB-23 1  cel ls  to H UVECs in a concentration-
dependent manner. 
Also, because the intercel lu lar  adhesion molecule ( I CAM)- 1 , has 
been shown to play an important role  in  the adhesion of cancer cel ls  to 
endothel ia l  cel ls and therefore in  metastasis, we sought to examine 
whether O M E  affects the expression of th is adhesion molecule in  MDA­
MB-2 3 1  cel ls .  Toward this a im,  cel ls  were treated with various 
concentrations of OME and the protein level of the ICAM-1 was 
determined by Western blotting .  As it is  shown in figure 64, the level of 
I CAM-1 protein  decreased in a concentration-dependent manner in  OME­
treated M DA-M B-231 cel ls.  Taken together, our results suggest that OME 
exerts a n  inh ibitory effect on  the adhesion of MDA-MB-231  cel ls  to 
H UVEC and that this effect is a ssociated with downregulation of ICAM-1 
protein .  
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Figure 63 .  I nh ibition of Adhesion of M DA-MB-231 Cel ls to H UVEC by O. 
majorana. 
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Figure 64. Western Blot Analysis of ICAM-1 Expression in O M E  Treated 
MD-MB-231 Cel ls. �-actin is used as loading control . 
3.25 O. majorana I n h ib ited Tra nsendothel ia l  M igrat ion of MDA-MB-
231  Through TN F-a-Stimu lated HUVECs 
Since the migration of tumor cel l s  th rough the vascular endothel ium 
is a nother crucial event in the metastasis process, we used the 
Transendothel ia l  Migration Assay to investigate the effect of OME on the 
abi l i ty of M DA-MB-231  cel ls to migrate across a monolayer of endothel ia l  
( H UVEC) cel ls .  As seen in  figure 65, the transendothel ia l  migration of 
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O M E  treatment through the monolayer of HUVEC was sign ificantly 
reduced by the treatment with O M E  in  a concentration-dependent manner. 
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Figure 65. O. majorana I nh ibited M igration of MDA-MB-23 1 Cel ls A cross 
Monolayer of TNF- a Activated H UVECs. 
3.26 O. majorana Suppressed VEGF Prod uction in HUVECs and 
M DA-M B-231 Cel ls  
Tumor growth and metastasis critica l ly depend on angiogenesis. 
VEGF ,  a pro-angiogenic growth factor, has been shown to play an 
i m portant role in  this process. Thus, we investigated the effect of OME on 
the production of VEG F by both the MDA-MB-23 1 and endothel ial  cel ls 
( H UVEC) with , and without, the presence of TN F-a. We first exam ined the 
effect of O M E  on basal expression levels of VEGF in M DA-MB-231  cel ls .  
Cel l s  were grown with various concentrations of OM E ,  the conditioned 
medium was col lected and the level of VEGF measured by EL ISA. Data 
shown in F igure 66 revealed that treatment with 300 and 450 �g/mL OME 
for 24 hours marked ly reduced the secretion of VEGF by MDA-MB-231  
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cel ls .  VEGF levels dropped from 1 300 pg/m L in the control to 800 and 400 
pg/m L respectively. To further confirm the inh ibition of VEGF production 
in breast cancer cel ls ,  we m easured the level of VEGF in MDA-MB-231 
cel l s  that were first treated with various concentration of OME and then 
stimu lated with TNF-a. As shown in figure 67, the production of VEGF was 
enhanced in TN F-a - stimu lated (2600 pg/mL) compared to vehicle-treated 
( 1 500 pg/mL) M DA-MB-2 3 1  cel ls .  However, VEGF production was 
sign ificantly reduced in a concentration-dependent manner by OME (fig .  
67) .  Next, we examined VEGF production in HUVECs. As expected , a 
HUVEC cultured in the absence of TNF-a produced low level of VEGF (20 
pg/m L) ,  whi le in the presence of TN F-a, VEGF production increased to 
approximately 1 20 pg/mL (fig .  68) .  Exposure of HUVEC to OME also led 
to a concentration-dependent suppression of VEGF production (fig .  68). 
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Figure 66. Quantification of Basa l  Level of VEGF Secretion in 
Conditioned Medium from Vehicle or OME Treated M DA-MB-231  Cells. 
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3.27 O. majorana I n h i b ited Phosphoryl ation of IKB ;  Downregulated 
N uclear Leve l of N FlCB 
The NFKB signa l ing pathway is known to regulate the expression of 
various genes involved in  tumor cel l  invasion . To investigate the effect of 
OME on the activation of the NFKB signal ing pathway, we first examined ,  
b y  Western blott ing, the phosphorylation status of I KB i n  OME-treated 
M DA-M B-23 1 cel ls .  We found that OME drastical ly inhibited the 
phosphorylation of I K B  (fig .  69). Moreover, we found that OME reduced 
the level of nuclear NFKB remarkably (fig .  70) .  Taken together, the data 
clearly indicates the OME exerts its effect at least partly through an 
inh ibition of the NFKB signal ing pathway. 
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Figure 69. Western Blot Analysis of the Phosphorylation Status of I KBa. 
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Figure 70.  Western B lot Analysis of  the Nuclear p65 (NFKB) .  [3-actin 
( loading contro l )  proteins. 
3.28 O. majorana Reduced N itr ic Oxide (NO) production in  MDA-MB-
231 Ce l ls  
Nitric oxide ( NO) signal ing has a lso been shown to promote breast 
tumor growth and metastasis by a ltering the expression of genes 
impl icated in  cel lu lar  m igration, invasion and angiogenesis [1 64- 1 66]. To 
test whether O M E  could affect the level of NO, the amount of n itrate/n itrite 
production was determined by ELISA in veh icle and OME-treated MDA-
MB-231 cel ls .  Results shown in figure 7 1  clearly show that OME 
decreased N O  production in a concentration-dependent manner in M DA-
MB-23 1 cel ls ,  thus suggesting that O M E  could a lso exert its anti-
metastatic effect by modulating the level of NO in breast cancer cel ls .  
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Figure 7 1 . Quantification of NO Levels in OME Treated MDA-MB-231  
Cel ls .  
3.29 O. majorana Inh ib ited Tumor G rowth and Metastasis in Chick 
Embryo Tumor Growth and Metastasis Assay 
To further confirm the in vitro anti-breast cancer activities of O. 
majorana, we decided to investigate i ts effect on tumor growth in vivo by 
using the chick embryo model . M DA-MB-23 1 cel ls were grafted on the 
chorioal lantoic membrane (CAM ) and formed tumors were treated every 
48 hours with vehicle, colchicine (2 I-l M )  or i ncreased concentrations of 
O M E  ( 300 and 450 I-lg/mL) .  At E 1 9, tumors were recovered from the 
upper CAM and weighed. As it is shown in figure 72 and 73 ,  OME 
sign ifica nt ly inh ibited tumor growth com pared with the control treatment. I n  
fact, concentrations of  300 and 450 I-lg/mL OME led to reduced tumor 
growth by 55 and 60% respectively. A simi lar effect (65% inhibition ) was 
obtained with 2 I-lM colchicine. Toxicity was evaluated by comparing the 
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num ber of dead embryos in O M E-treated and control (vehicle-and 
colchicine-treated ) embryos. We found that OME showed no toxicity to the 
embryo (data not shown ). 
We next assessed for the abi l ity of OME to inh ibit metastasis by 
counting the number of nodu les in the lower CAM in veh icle, colchicine 
and O M E  treated tumors. An average of 6 .6 nodules were counted in the 
lower CAM of vehicle-treated chick embryo , wh i le an average of only 1 . 1 
nodu les were counted in 300 a nd 450 �g/mL OME-treated embryos ( fig .  
74) .  The data clearly demonstrates that OME could efficiently inh ibit 
breast tumor growth and metastasis in vivo. 
Vehicle or.1 E (JOO 1l91mL) ol.le 1450 119 mL) Colchlcane 12 Il',') 
Figure 72.  Anti-tumor Growth of O. majorana on Breast Tumor in a 
Chick Embryo Chorioal lantoic Membrane Model System . 
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DISC USSION 
Common cancer treatment drugs a im at  inh ib iting cell cycle 
progression and at inducing cel l death and apoptosis. Cancer 
chemoprevention through these two events (cell cycle arrest and 
apoptosis) has been reported for several natural com pounds [2 1 ,  1 67-70] . 
I n  the present study, we have shown that extract of an ethanolic 
fraction of Origanum majorana i nh ibited the proliferation of mutant p53 
trip le negative breast cancer (TNBC) cel l l ine,  MDA-MB-231 . We have 
a lso demonstrated that O M E  induces a d ifferentia l  concentration­
dependent effect on these cel ls .  OME induces a cell cycle arrest at the 
G2/M phase and more precisely a mitotic arrest at low concentrations.  
Th is  finding i s  supported by a body of evidence: ( i )  an increase in  the level 
of p(ser1 0)H3,  a mitotic marker, and ( i i )  an increase of cycl in B1 protein 
level , whose upregulation was reported in several m i totica l ly arrested 
cel ls .  We have also shown that cell cycle arrest correlates with an 
u pregu lation of the CDK inh ibitor p2 1 and the anti-apoptotic prote in ,  
survivin .  At h igh concentrations ,  however, OME induced a massive 
a poptosis demonstrated by a dramatic increase in  the sub-G 1 population . 
We have demonstrated that OME exerts i ts apoptotic effect by activating 
the cel l  death extrins ic pathway, at least partia l ly ,  via the activation of 
T NF-a. We have also shown that OME-induced apoptosis is mediated by 
an increase in DNA damage, revealed by an upregulation of yH2AX, 
severe depletion of the m utant p53 and survivin prote ins from the treated 
cel l s .  
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The process of apoptosis can be induced either by the extrinsIc 
pathway which involves signa l ing from death receptors at the cel l  surface 
or by the intri nsic m itochondria-mediated pathway [ 1 7 1 ] . Activation of the 
death receptor-mediated apoptosis requ i res the interaction of l igands such 
as TN F-a and Fas with thei r  transmembrane receptors [ 1 72]. The l igand­
receptor interaction leads to the activation of the effector Caspase 8, 
which in  turn activates the effector Caspase 3 d i rectly and/or through 
m itochondria [ 1 73] . The mitochondria-mediated apoptosis pathway is  
associated with permeabi l ization of the mitochondria outer membrane, 
reduced mitochondrial membrane potential (l:ltf.1m ), change in  expression 
of the anti -apoptotic Bcl2 fami ly members, such as Bcl2 and BcI-XL and 
the pro-apoptotic members such as Bax and Bak lead to the formation of 
apoptosome, activation of Caspase 9 and consequently activation of 
caspase 3 [ 1 74] . I ntrins ic- and extrinsic-pathways activated Caspase 3 ,  
cleave PARP,  thus  resu lt ing i n  apoptosis [ 1 75] .  I n  the present study, we 
showed that OME induced a TNF-a-mediated extrins ic apoptotic pathway. 
A TNF-a receptor was activated at 24 hours and induced downstream 
signal ing such as Caspase 8, caspase 3, and PARP cleavage. On the 
other hand, OME d id  not induce mitochondria-mediated apoptotic pathway 
since no change in the BAXlBcl2 ratio or activation of Caspase 9 were 
detected . We suggest that OME induces apoptosis solely th rough a TNF-a 
activated signal pathway in M DA-MB-231  cel l s. 
Studies have reported that DNA damage is  one of the molecular 
events associated with cel l  cycle arrest and apoptosis. I ndeed, many anti ­
cancer drugs have been shown to induce DNA damage [1 76] [1 77] .  
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Moreover. cancer cel ls are reported to be more susceptible than normal 
cel ls  to DNA damaging agents [ 1 78] . therefore there is a growing i nterest 
i n  d ietary phytochemica ls  that possess DNA-damaging activity. In the 
present study we showed that OME el icited DNA damage measured by an 
increase in  a concentration-dependent manner of the marker of DNA 
damage, y-H2AX. after treatment with OME for 6 or 24 hours. The 
differential response to the different concentrations of OME (G2/M arrest 
and/or apoptosis). may be partia l ly mediated by the extent of DNA 
damage that occurs with in  the genome. Low levels of DNA damage may 
trigger recru itment of DNA repair  complexes. expression of anti-apoptotic 
and survival prote ins leading to arrested cel l  cycle unti l  the genotoxic 
lesions are repaired . I n  th is  case, survival proteins such as survivin get 
activated in order to mainta in  the viabi l i ty of G2/M arrested cel ls .  On the 
other hand . when genomes are overwhelmed by DNA damage. cel ls are 
e l iminated by apoptosis [ 1 79, 1 80] . I n  th is study, we have found that h igh 
concentrations of OME triggered high level of DNA damage to the 
genome.  causing cel l  to enter apoptosis .  Our data suggest that Origanum 
majorana possess a genotoxic effect on M DA-MB-231  cel ls .  At th is stage. 
the mechanism(s) by wh ich OME induces DNA damage remain(s) 
unknown, and certa in ly  deserves further study. 
I nh ibitor of apoptosis proteins ( lAPs), which includes survivin ,  
represents a fam i ly of anti -apoptotic proteins that bind and inactivate 
active Caspase 3/7 [ 1 46, 1 47] and Caspase 9 [ 1 48] and can modulate cel l  
d ivision and cell cycle progression [ 1 49] . 
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I n terestingly,  survivin has no effect on Caspase 8 activity. Survivin has 
been shown to be h igh ly expressed in  most cancers, where it functions as 
an inh ibitor of apoptosis .  In breast cancer, overexpressed survivin was 
shown to protect cel ls  against apoptosis induced by chemotherapeutic 
agents, such as etoposide [ 1 46] . Based on these reports, survivin proteins 
represents an attractive target of particular importance in  cancer therapy 
at large and in breast cancer therapy in particular.  I n  consideration of the 
recognized role for survivin as a custodian of cancer cell surviva l ,  our 
resu lts suggest that OME m ight exert i ts cytotoxic anti -cancer effects, at 
least partly via the downregu lation of survivi n .  In our study, we have 
shown that survivin expression is d ifferentia l ly regulated in a 
concentration-dependent manner by OME.  Lower concentrations of OME 
induced an u pregulation of survivin wh ich causes cel ls  to arrest the cell 
d ivision and to resist a poptosis by inh ibit ing the cel l death program. I n  
fact, w e  showed that i n  these arrested cel is ,  PARP cleavage was not 
detected despite the activation of Caspase 3/7 . This effect might be 
m ediated by the inh ibit ion of active 3/7 by the upregu lated survivin .  
Survivn function could a lso account for the mitotic arrest induced by OME.  
I n  fact, survivin ,  has a lso been shown to be requ ired for mitotic arrest of 
HeLa cel ls induced by the anti -cancer drug UCN-0 1 [ 1 8 1 ] . 
The tumor suppressor protein ,  p53 is found to be mutated in about 
50% of human cancers [ 1 50].  Mutant p53 is reported to play a key role in  
cancer cells resistance to certain anti -cancer drugs and thus is considered 
as  a potential cancer-specific target for pharmacologic interventions [ 1 82] . 
[ 1 83] . Studies have shown that inh ibition of mutant p53 by RNA 
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interference sensitizes cancer cell to cell death by chemotherapeutic 
agents [1 84] . Wang et a l .  201 1 ,  showed that the naturally occurring 
i sothiocyanate ( ITC) phenetyl i sothiocyanate ( P E I TC),  derived from the 
watercress plant, and the synthetic lTC, 2 ,2-di phenetyl isothiocyanate 
select ively deplete m utant, but not the wi ld -type p53, and induce 
apoptosis in many cancer cel ls, including MDA-MB-231  breast cancer 
cel ls [ 1 85] . Here, we showed that OME led to a dramatic decrease in the 
mutant p53 level in M DA-MB-231 cel ls .  As such , mutant p53 depletion 
may be an important target for chemoprevention and therapy by O. 
majorana for TNBC.  
Increase in  the expression of the cycl in-dependent kinase inh ibi tor, 
p2 1 has been shown to augment G2/M arrest via a p53-independent 
m echanism in human breast cancer [ 1 86] . In most cases, growth arrest 
was found to be associated with apoptosis. I n  th is study, we showed that 
low concentrations of O M E  treatment led to G2/M arrest without significant 
increase in cell death after 24 hours treatment. H istone hyperacetylation 
has been demonstrated to be directly l inked to the upregu lation of p2 1 and 
this activation can a lso occur independently of p53 [1 87] . Moreover, 
h i stone hyperacetylation was also shown to be associated with growth 
suppression and apoptosis .  Our data showed that OME induced histone 
H3 and H4 hyperacetylation in  MDA-MB-231 cel ls, suggesting that the 
anti -breast cancer effects of OME were at least partly mediated by 
H istone H3 and H4 hyperacetylation by regu lating the expression of the 
genes control l ing these two events. The mechanism by which OME 
induces h istone hyperacetylation might involve a H istone Deacetylase 
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I nh ibitor ( H O I )  activity. Interestingly, the plant, O. majorana, contains 
l uteol i n ,  a d ietary flavonoid with HOI  activity [98] . I n  fact, luteol in was able 
to decrease the viabi l ity of lung, colon , l iver and breast cancer cel ls and 
induce hyperacetylation of h istone H3 and H4 [1 88] . In l ight of th is,  we 
conclude that the H istone hyperacetylation induced by OME is involved 
with the HO I  activity of luteol in .  We are currently undertaking further 
investigations to better understand the mechan ism(s) by which OME 
induces H istone hyperacetylation .  
I n  conclusion ,  o u r  data is  consistent with the model shown in figure 
75 which shows the concentration-dependent differential effect of O. 
majorana extract on mutant p53, triple negative MOA-MB-231  cel ls .  At low 
concentrations ,  O M E  induced a m itotic arrest associated with low level of 
DNA damage (75 ,  th in arrow), upregulation of the COK inhibitor p2 1 and 
the inh ibitor of apoptosis, survivin .  We bel ieve that these events along 
with other yet to be identified events contribute to the cel l cycle arrest. I n  
addit ion we a lso propose that, a t  these concentrations, survivn i s  also 
impl icated i n  the blockage of the TNF-mediated apoptosis pathway, by 
d i rectly inh ibiti ng the activity of the active Caspase 3 .  On the other hand , 
h igh concentrations ,  OME induce massive apoptosis via the activation of 
the TN F-a extrinsIc pathway wh ich is associated with high level of DNA 
damage (fig .  75, thick arrow) and almost complete depletion of the mutant 
p53 and surviving proteins from these cel ls .  Our findings provide the first 
i nstance of a potential role for OME as an anti-breast cancer agent in vitro 
which certa in ly  deserves more attention and further exploration to identify 
novel com pounds for breast cancer. 
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Figure 7 5 .  Proposed Mechanisms of Action of O. majorana o n  MDA-MB-
231  Cel ls. 
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Tumor invasion and metastasis IS a multistep process involving cell 
adhesion , proteolytic degradation and m igration through the ECM and 
angiogenesis. Common cancer treatment drugs aim at blocking cell cycle 
progression , inducing cel l  death and/or inh ibiting tumor migration and 
invasion . Cancer chemoprevention through these events has been 
reported for several natural com pounds [2 1 ]  [1 67- 1 70] . Nowadays, there 
is  a growing interest in combination therapy using mu ltiple anti-cancer 
drugs affecting several targets/pathways. Herein ,  we demonstrate for the 
first t ime that O. majorana, at non-cytotoxic concentrations, possesses 
potent anti-metastatic properties against the highly invasive trip le negative 
breast cancer cell l ine,  MDA-MB-231 . In fact, O. majorana efficiently 
inh ib ited the migratory abi l ities and induced homotypic aggregation of 
M DA-MB-2 3 1  cel ls ,  associated with an upregu lation of E-cadherin 
expression.  We also showed that O. majorana not only decreased the 
adhesion of M DA-M B-23 1 to H UVECs as well as their transendothelial 
migration ,  but a lso inhibited the secretion of the pro-angiogenic factor 
VEGF from both endothel ial and breast cancer cel ls .  I n  addition we 
demonstrate that O. majorana suppressed the expression and the 
activit ies of M M P-2 and MMP-9 and downregu lated the expression of 
u PAR and I CAM-1 . 0. majorana a lso blocked IKB-a/N FKB and reduced 
N itric Oxide ( NO) production , both signal ing events involved in cancer cell 
invasion .  Moreover, we demonstrated that O. majorana significantly 
inh ib ited tumor growth and metastasis in vivo in a chick tumor growth 
assay. 
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I t  i s  well known that d isruption of cell -cel l adhesion during cancer 
progression IS the in it ial stage required for the acquisition of invasive 
properties. Decreased cel l-cel l adhesion in cancer cel ls is often 
characterized by d imin ish ed expression of E-cadherin .  Indeed , E­
cadherin ,  a calc ium-dependent, cel l  adhesion molecu le,  is  considered as 
a tumor suppressor in breast cancer [1 89] . A decrease in E-cadherin 
expression i s  a critical and necessary event requ ired in  the disruption of 
cel l -cel l  adhesion and thus for the acquisition of invasive phenotype of 
various tumors including breast cancer. I n  fact, downregulation or loss of 
E-cadherin during cancer progression is associated with aggressive 
behavior by the tumor and a poor prognosis for the patient [ 1 90] . 
Conversely, expression of E-cadherin can lead to a reduced progression 
and i nvasion of breast cancer cel l s  [1 91 ] .  In the present study, we 
demonstrated that O. majorana inh ibited cel l  m igration and promoted 
homotypic cel l-cel l  aggregation and induced overexpression of E-cadherin 
in the M DA-MB-231 cel ls .  We postu late that O. majorana exerts its anti­
m igratory effect on breast cancer cel ls ,  at least partly, through reactivation 
of the expression of E-cadherin gene. In fact we showed that OME was 
ab le to induce transactivation of E-cadherin promoter in transfected cel ls 
( Fig . 3D) .  I nduction of E-cadherin expression promotes then homotypic 
aggregation of OME-treated MDA-M B-231 cel ls .  Thus, E-cadherin 
overexpression is one of possible mechan ism by wh ich O. majorana 
exerts i ts anti- invasive effect on the MDA-MB-231  cel ls. 
Recent studies showed that treatment with h istone deacetylase 
inh ib itors such as SAHA and trichostatin A strongly inh ibited the migration 
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and i nvasion of breast and prostate cancer cel ls  and caused an 
u pregulation of E-cadherin [ 1 92 ,  1 93]. H istone Deacetylase ( HDAC) 
I nh ibitors, promising anticancer agents, have been shown to med iate their 
effects by activating the transcription of specific genes through histone 
hyperacetylation . Interestingly,  we have recently shown that O. majorana 
induces hyperacetylation of H istone H3 and H4 at non-cytotoxic 
concentrations.  Moreover, O. majorana has been shown to contain 
luteo l in  [98] ,  a d ietary flavonoid with Histone Deacetylase Inh ibitor activity, 
which was a lso shown to inh ibit the invasive potential  of MDA-MB-231 
cel l s  [ 1 88] . 
Based on these findings, we can suggest that one possible 
m echanism by which O. majorana exerts i ts anti-m igratory and anti­
m etastatic effects on M DA-MB-231 involves an upregulation of E-cadherin 
gene expression through H istone hyperacetylation .  However, at th is 
stage,  we cannot ru le out the i nvolvement of other m echan ism(s) being 
involved in th is regulation . Further investigation will be needed to decipher 
the exact mechanism by which O. majorana exert its effect on E-cadherin 
expression.  
The d issemi nation of cancer cel ls from the primary tumor is another 
crucial  event in the process of cancer invasion and metastasis, which 
involves the degradation of the ECM and the components of the basement 
membrane through proteases. Of these proteases, MMPs such as MMP-
2 ,  MMP-9 and the u PA are thought to play a key role  in  cancer cel l  
i nvasion and metastasis [ 1 94,  1 95] . I t  has  been shown that increasing 
expression of MMPs in  breast cancer cel ls correlates with increasing 
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aggressiveness of breast cancer cell growth and metastatic potential 
[ 1 96] . T herefore, inhibit ing the activity or the expression of these 
proteases can be considered as a potential therapeutic target against 
breast cancer. Interestingly, here we clearly demonstrate that O. 
maJorana exerts i ts anti-invasive affect against MDA-MB-231  cel ls by 
sign i ficant ly downregu lating the expression of uPAR, MMP-2 and MMP-9 
and decreasing the activity of these two proteases and consequently 
red ucing ECM degradation . 
The abi l ity of tumor cel ls  to m etastasize also largely depends on 
their  ab i l i ty to adhere and transmigrate though endothel ial cel ls .  Cancer 
cell-endothel ia l  cel l  interaction is m ediated by various adhesive molecules 
such as intracel lu lar adhesion molecu le-1 ( I CAM- 1 ) , vascu lar cel l  
adhesion molecule-1 (VCAM- 1 ) and E- selectin [ 1 97]. Studies have shown 
that the level of ICAM- 1 protei n  expression on the cel l surface positively 
correlated with metastatic potential of several breast cancer cel l  l ines [ 1 6]. 
Moreover, down regu lation of I CAM-1 at the protein and m RNA levels 
strongly i nh ibited human breast cancer cel l invasion [ 1 6] .  Tanshimone I ,  a 
natura l  com pound derived from m edicinal plant, Salvia miltiorrhiza , 
efficient ly i nh ib ited the adhesion of M DA-MB-231 cel ls  to H UVECs by 
down regu lat ing the expression of I CAM- 1 and VCAM-1  [ 1 98] . Recent 
stud ies have revealed that ICAM-1 expression is associated with a more 
aggressive breast tumor phenotype [ 1 99] . Based on these findings, ICAM-
1 represents a potential target i n  breast cancer treatment. Our study 
revealed that O. majorana was able to reduce the expression levels of 
ICAM- 1 prote ins in  MDA-MB-23 1  cel ls  and blocked their adhesion to the 
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h uman vascular endothel ia l  cel l s  ( HUVECs). Hence. we propose that 
downregu lation of ICAM-1 expression could be one mechanism by which 
O. majorana blocks MDA-MB-23 1  cel ls  capabi l ity to adhere to HUVECs 
and consequently prevents their metastasis. 
Angiogenesis .  a process by which new blood vessels form . is 
crucia l  for tumor growth and metastasis. Blockade of angiogenesis can 
inh ibit both tumor growth and metastasis [200] .  Thus inhibition of 
angiogenesis can be considered as a promising strategy in cancer therapy 
[20 1 ,  202].  One possib le way to b lock ang iogenesis is to target pro­
a ngiogenic factors secreted by tumor cel ls .  VEGF is the major pro­
angiogenic protein expressed in 60% of breast cancer patients at the time 
of first d iagnosis [203] . I nterestingly, we found that O. majorana 
sign ificantly reduced the production of VEGF in both H UVECs and MDA­
M B-23 1  cel ls.  suggesting that OME not only inhibits breast cancer cell 
invasion . but cou ld a lso b lock angiogenesis .  
The N FKB signal ing pathway is known to regu late the expression of 
various genes involved in the process of tumor metastasis. E levated 
levels of N FK B  are frequently detected in breast cancer cel ls .  Studies 
showed that inh ibition of NFKB activity could suppress metastasis in 
breast cancer cel ls .  In fact. studies showed that inactivation of N FKB in 
M DA-MB-231  breast cancer cel ls inh ibit the expression of many 
downstream target genes involved in tumor metastasis such as MMP-2 
[ 1 96] . M M P-9 [26 .  204. 205]. VEGF [205]. ICAM-1 [26] and u PAR [26] . 
The phosphorylation of I KB .  by the I KK� subunit of the I KK serine kinase 
complex. is a crucial step in the activation of NFKB.  
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I n  fact, phosphorylation of IKB triggers i ts polyubiquitmation and 
proteasome-mediated degradation with consequent NFKB nuclear 
loca l ization [206] .  Nuclear N FKB can then upregulate the transcription of 
its target genes. Therefore, one way to inactivate the activated NFKB 
signal ing in  cancer cel ls  i s  to block the phosphorylation of I Kb by 
inactivating the IKK com plex. Interestingly, in the present work, we 
demonstrated that O. majorana inh ibited the phosphorylation of I KB and 
reduced the protein level of nuclear NFKB suggesting that 0. majorana 
may negatively regu late the activity of N FKB possibly by affecting the 
activity of the I KK com plex. I t  is  worth mention ing that O. majorana 
sign ificantly reduced the expression of several NFKB downstream target 
genes ( MMP-2, MMP-9, u PAR, ICAM-1 and VEG F) involved in tumor 
m etastasis .  I t  appears that the inh ibitory effect on NFKB could account for 
the a nti-metastatic effects of O. majorana. 
N itric Oxide (NO) ,  synthesized by several n itric oxide synthases 
( N OSs),  nNOS/NOS-1 ,  i NOS/NOS2 and eNOS/NOS3 is a signal ing 
molecule that regu lates several physiological  responses such as 
vasod i latation , cell m igration ,  immune reactions and apoptosis [ 1 98]. 
I n terestingly, various stud ies have shown that NO can both promote and 
i nh ibit tumor progression and metastasis. The pro- or anti-tumorigenic 
activit ies of NO have been related to the p53 status [ 1 66, 207] .  I t  has been 
shown that NO-mediated apoptosis in leukem ia cel ls requ ires wild-type 
p53 [208] . On the other hand , it has been shown that iNOS/NOS2 
expressing carcinoma cel ls with mutant p53 have accelerated tumor 
growth and i ncreased VEGF production [209] . NO was shown to promote 
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cancer progression through the activation of oncogenic signal ing 
pathways including the extracel lu lar signal-regu lated kinases ( ERK) 1 /2 ,  
phosphoinositide 3-kinases (P I3K)/AKT, and c-Myc [ 1 24]. Recent studies 
showed that increased iNOS/NOS2 and consequently NO production , 
predicted poor survival In  women with estrogen receptor a-negative ( E R­
negative) breast tumors. Moreover, exposure to NO enhanced cel l motil ity 
and invasion of Estrogen Receptor negative ER( -) cel ls [209] . It appears 
then that d iscovery of inh ibitors targeting NO production may be 
particularly efficacious against ER( -), mutant p53 breast cancer patients. 
In the present study we showed that O. majorana efficiently reduced the 
level of NO production in the M DA-MB-231 in a concentration dependent 
manner, suggesting that O. majorana might exert its anti-metastatic effect, 
at least part ly, by modu lating the NO production in M DA-MB-23 1 cel ls .  As 
such , NO production may be an important target for chemoprevention 
and therapy by O. majorana for the E R(-) ,  mutant p53 M DA-MB-231 cel ls .  
In  summary, th is study clearly demonstrated , for the first t ime,  that 
O. majorana possesses anti-i nvasive and anti-metastatic effects against 
h igh ly prol iferative and h igh ly invasive human MDA-M B-23 1 breast cancer 
cel l  l ine by modu lating the activity and/or the expression of proteins 
regulating the process of cel lu lar migration , adhesion invasion and 
angiogenesis such as E-cadherin ,  ICAM-1 , MMP-2, MMP-9, uPAR and 
VEGF,  at least partly ,  th rough inh ibition of the NFKB and NO signal ing 
pathways. Our resu lts a lso showed that O. majorana inhibited tumor 
growth and metastasis in an in vivo tumor growth assay. Thus, our current 
study identifies Origanum majorana as a promising chemopreventive and 
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therapeutic candidate that inh ibits breast cancer growth and metastasis by 
modulating the expression and activities of several targets . Nowadays, 
there is  a growing interest in combination therapy using multiple anti ­
cancer drugs affecting several targets/pathways, thus O. majorana 
certain ly merits a lot of attention and further exploration to identify novel 
com pounds for breast cancer therapy. 
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G E N ERAL C O N C LUSION 
I n  conclusion,  our study has focused o n  natural products such a s  
plant extracts a n d  natural compounds found i n  nature and in  our d iets as 
potentia l  ant i-breast cancer agents. We demonstrated that Sal i nomycin 
induces apoptosis and senescence in breast cancer th rough upregu lation 
of p2 1 ,  downregulation of survivin and Histone H3 and H4 
hyperacetylation . Further, we provided evidence that Origanum majorana 
attenuates breast cancer cel l  invasion,  migration and tumor growth in vivo, 
at least in  part ,  through inh ibit ing the N FlCB activation cascade and 
reduction of N i tric Oxide production.  In recent years, an increasing 
number of natura l  products possessing anti -cancer properties have been 
uncovered . Coupled with the elucidation of their anti -cancer mechanisms, 
the exploitation of their  use in  cl inical chemotherapeutic strategies is  
promis ing.  A potential advantage of phytochemicals and other compounds 
derived from natura l  products is that they may act through mult ip le cel l 
signal ing pathways and reduce the development of resistance by cancer 
cel ls .  Thus, natura l  products and natura l ly  occurring phytochemica ls  a re 
indeed worthy of further development as anti -cancer and anti-metastatic 
agents for cl i n i ca l  u se.  
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